Tofacitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 8, 2026

The clinical evidence base for Tofacitinib comprises 448 peer-reviewed publications across 15 journals, 46 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Rheumatoid, and Alopecia Areata. Most recent publication: Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis., Rheumatol Ther, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

JAAD Game Changers: Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Wohltmann WE · J Am Acad Dermatol · 2024
PubMed: PMID 38823686 · NCT07101471 · Alopecia Areata
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
van der Heijde D, Deodhar A, Wei JC, et al. · Ann Rheum Dis · 2017
PubMed: PMID 28130206 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal.
Tsakok T, Jabbar-Lopez ZK, Smith CH, et al. · Br J Dermatol · 2019
PubMed: PMID 29399784 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, et al. · Br J Dermatol · 2016
PubMed: PMID 26357944 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P, Hall S, FitzGerald O, et al. · N Engl J Med · 2017
PubMed: PMID 29045212 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY, Craiglow BG, Dai F, et al. · J Am Acad Dermatol · 2017
PubMed: PMID 27816293 · NCT07101471 · Alopecia Areata
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D, Rigby W, Azevedo VF, et al. · N Engl J Med · 2017
PubMed: PMID 29045207 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W, King BA · J Am Acad Dermatol · 2017
PubMed: PMID 28139263 · NCT06278402 · Alopecia Areata

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT01458951 OCTAVE	Colitis, Ulcerative	Percentage of Participants With Remission at Week 8 Week 8	Placebo BID	3.6 percentage of participants
NCT01458951 OCTAVE	Colitis, Ulcerative	Percentage of Participants With Remission at Week 8 Week 8	Tofacitinib 10 mg BID	16.6 percentage of participants
NCT01465763 OCTAVE	Colitis, Ulcerative	Percentage of Participants With Remission at Week 8 Week 8	Placebo BID	8.2 percentage of participants
NCT01465763 OCTAVE	Colitis, Ulcerative	Percentage of Participants With Remission at Week 8 Week 8	Tofacitinib 10 mg BID	18.5 percentage of participants
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 12 and Its Change From Baseline at Month 12 Baseline, Month 12	Tofacitinib 5 mg BID (Open-label)	49.16 Kilograms (±20.59 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	6.52 Kilograms (±6.71 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 24 and Its Change From Baseline at Month 24 Baseline, Month 24	Tofacitinib 5 mg BID (Open-label)	52.42 Kilograms (±20.15 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	9.42 Kilograms (±8.08 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 36 and Its Change From Baseline at Month 36 Baseline, Month 36	Tofacitinib 5 mg BID (Open-label)	12.44 Kilograms (±10.34 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	56.96 Kilograms (±19.96 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 48 and Its Change From Baseline at Month 48 Baseline, Month 48	Tofacitinib 5 mg BID (Open-label)	56.72 Kilograms (±17.69 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	13.99 Kilograms (±11.06 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 60 and Its Change From Baseline at Month 60 Baseline, Month 60	Tofacitinib 5 mg BID (Open-label)	17.50 Kilograms (±11.99 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	58.07 Kilograms (±18.28 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 72 and Its Change From Baseline at Month 72 Baseline, Month 72	Tofacitinib 5 mg BID (Open-label)	20.55 Kilograms (±13.49 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	58.38 Kilograms (±19.40 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Body Weight at Month 84 and Its Change From Baseline at Month 84 Baseline, Month 84	Tofacitinib 5 mg BID (Open-label)	59.31 Kilograms (±18.24 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	23.80 Kilograms (±12.46 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Baseline At Baseline	Tofacitinib 5 mg BID (Open-label)	141.36 Centimeters (±23.62 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 12 and Its Change From Baseline at Month 12 Baseline, Month 12	Tofacitinib 5 mg BID (Open-label)	147.87 Centimeters (±20.92 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	5.55 Centimeters (±5.66 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 24 and Its Change From Baseline at Month 24 Baseline, Month 24	Tofacitinib 5 mg BID (Open-label)	9.30 Centimeters (±7.96 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	151.60 Centimeters (±19.34 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 36 and Its Change From Baseline at Month 36 Baseline, Month 36	Tofacitinib 5 mg BID (Open-label)	155.76 Centimeters (±16.05 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	10.97 Centimeters (±10.49 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 48 and Its Change From Baseline at Month 48 Baseline, Month 48	Tofacitinib 5 mg BID (Open-label)	14.07 Centimeters (±12.55 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	157.82 Centimeters (±14.81 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 60 and Its Change From Baseline at Month 60 Baseline, Month 60	Tofacitinib 5 mg BID (Open-label)	158.92 Centimeters (±14.15 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	17.71 Centimeters (±14.86 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 72 and Its Change From Baseline at Month 72 Baseline, Month 72	Tofacitinib 5 mg BID (Open-label)	22.92 Centimeters (±16.35 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	159.76 Centimeters (±14.41 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Value of Height at Month 84 and Its Change From Baseline at Month 84 Baseline, Month 84	Tofacitinib 5 mg BID (Open-label)	163.15 Centimeters (±11.00 Standard Deviation)
NCT01500551	Arthritis, Juvenile		Tofacitinib 5 mg BID (Open-label)	27.95 Centimeters (±18.02 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Absolute Values of Body Weight at Baseline At Baseline	Tofacitinib 5 mg BID (Open-label)	41.60 Kilograms (±19.35 Standard Deviation)
NCT01500551	Arthritis, Juvenile	Number of Participants According to Tanner Stage at Baseline At Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap)	Tofacitinib 5 mg BID (Open-label)	9 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	39 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	11 Participants
			Tofacitinib 5 mg BID (Open-label)	14 Participants
			Tofacitinib 5 mg BID (Open-label)	14 Participants
			Tofacitinib 5 mg BID (Open-label)	13 Participants
			Tofacitinib 5 mg BID (Open-label)	9 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	53 Participants
			Tofacitinib 5 mg BID (Open-label)	47 Participants
			Tofacitinib 5 mg BID (Open-label)	11 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	14 Participants
			Tofacitinib 5 mg BID (Open-label)	13 Participants
			Tofacitinib 5 mg BID (Open-label)	19 Participants
			Tofacitinib 5 mg BID (Open-label)	27 Participants
			Tofacitinib 5 mg BID (Open-label)	34 Participants
			Tofacitinib 5 mg BID (Open-label)	34 Participants
			Tofacitinib 5 mg BID (Open-label)	44 Participants
			Tofacitinib 5 mg BID (Open-label)	12 Participants
			Tofacitinib 5 mg BID (Open-label)	12 Participants
			Tofacitinib 5 mg BID (Open-label)	26 Participants
			Tofacitinib 5 mg BID (Open-label)	26 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Laboratory Test Abnormalities During study treatment (maximum up to 118 months)	Tofacitinib 5 mg BID (Open-label)	294 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 12 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 12	Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	17 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	18 Participants
			Tofacitinib 5 mg BID (Open-label)	11 Participants
			Tofacitinib 5 mg BID (Open-label)	11 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	33 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	20 Participants
			Tofacitinib 5 mg BID (Open-label)	9 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	9 Participants
			Tofacitinib 5 mg BID (Open-label)	12 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	35 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	18 Participants
			Tofacitinib 5 mg BID (Open-label)	12 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	13 Participants
			Tofacitinib 5 mg BID (Open-label)	30 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	11 Participants
			Tofacitinib 5 mg BID (Open-label)	34 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
Tofacitinib 5 mg BID (Open-label)	8 Participants
Tofacitinib 5 mg BID (Open-label)	6 Participants
Tofacitinib 5 mg BID (Open-label)	6 Participants
Tofacitinib 5 mg BID (Open-label)	5 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	2 Participants
Tofacitinib 5 mg BID (Open-label)	7 Participants
Tofacitinib 5 mg BID (Open-label)	2 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	4 Participants
Tofacitinib 5 mg BID (Open-label)	2 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	2 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	7 Participants
Tofacitinib 5 mg BID (Open-label)	5 Participants
Tofacitinib 5 mg BID (Open-label)	8 Participants
Tofacitinib 5 mg BID (Open-label)	2 Participants
Tofacitinib 5 mg BID (Open-label)	4 Participants
Tofacitinib 5 mg BID (Open-label)	3 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 24 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 24	Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	7 Participants
			Tofacitinib 5 mg BID (Open-label)	7 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	15 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	13 Participants
			Tofacitinib 5 mg BID (Open-label)	7 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	15 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	24 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
Tofacitinib 5 mg BID (Open-label)	12 Participants
Tofacitinib 5 mg BID (Open-label)	6 Participants
Tofacitinib 5 mg BID (Open-label)	16 Participants
Tofacitinib 5 mg BID (Open-label)	21 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 36 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 36	Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	12 Participants
			Tofacitinib 5 mg BID (Open-label)	24 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	12 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	16 Participants
			Tofacitinib 5 mg BID (Open-label)	17 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	7 Participants
			Tofacitinib 5 mg BID (Open-label)	7 Participants
			Tofacitinib 5 mg BID (Open-label)	7 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	1 Participants
Tofacitinib 5 mg BID (Open-label)	2 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 48 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 48	Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	17 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
			Tofacitinib 5 mg BID (Open-label)	14 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	4 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	5 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 60 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 60	Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	9 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	6 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	8 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 72 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 72	Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	3 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Shift in Tanner Stage From Baseline to Month 84 Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 84	Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
			Tofacitinib 5 mg BID (Open-label)	2 Participants
			Tofacitinib 5 mg BID (Open-label)	1 Participants
NCT01500551	Arthritis, Juvenile	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention)	Tofacitinib 5 mg BID (Open-label)	268 Participants
NCT01877668 OPAL BROADEN	Arthritis, Psoriatic	Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score From Baseline to Month 3	Adalimumab, 40 mg, Every 2 Weeks	-0.4259 Units on a scale (±0.05227 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.3736 Units on a scale (±0.04719 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.4304 Units on a scale (±0.05143 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.4478 Units on a scale (±0.05426 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.2129 Units on a scale (±0.04246 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.3808 Units on a scale (±0.04767 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.3643 Units on a scale (±0.05069 Standard Error)
			Adalimumab, 40 mg, Every 2 Weeks	-0.3028 Units on a scale (±0.04465 Standard Error)
			Placebo	-0.1802 Units on a scale (±0.05031 Standard Error)
			Placebo	-0.0837 Units on a scale (±0.04549 Standard Error)
			Placebo	NA Units on a scale (±NA Standard Error)
			Placebo	NA Units on a scale (±NA Standard Error)
			Placebo	NA Units on a scale (±NA Standard Error)
			Placebo	NA Units on a scale (±NA Standard Error)
			Placebo	-0.1682 Units on a scale (±0.04998 Standard Error)
			Placebo	-0.1224 Units on a scale (±0.04755 Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	NA Units on a scale (±NA Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	NA Units on a scale (±NA Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	-0.3841 Units on a scale (±0.07369 Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	NA Units on a scale (±NA Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	-0.4839 Units on a scale (±0.07276 Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	-0.3302 Units on a scale (±0.07128 Standard Error)
			Placebo/Tofacitinib, 10 mg, Twice Daily	-0.4569 Units on a scale (±0.07704 Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	-0.3843 Units on a scale (±0.07185 Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	NA Units on a scale (±NA Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	NA Units on a scale (±NA Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	-0.3142 Units on a scale (±0.07315 Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	-0.4104 Units on a scale (±0.07646 Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	-0.2850 Units on a scale (±0.07075 Standard Error)
			Placebo/Tofacitinib, 5 mg, Twice Daily	NA Units on a scale (±NA Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.5104 Units on a scale (±0.05365 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.4407 Units on a scale (±0.05039 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.2676 Units on a scale (±0.04426 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.4009 Units on a scale (±0.04678 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.4611 Units on a scale (±0.05179 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.4847 Units on a scale (±0.05096 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.2089 Units on a scale (±0.04208 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.3998 Units on a scale (±0.04716 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.4471 Units on a scale (±0.05136 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.3499 Units on a scale (±0.04665 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.2713 Units on a scale (±0.04626 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.5119 Units on a scale (±0.05038 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.4231 Units on a scale (±0.04982 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.1842 Units on a scale (±0.04131 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.5391 Units on a scale (±0.05324 Standard Error)
			Tofacitinib, 5 mg, Twice Daily	-0.2048 Units on a scale (±0.04363 Standard Error)
NCT01877668 OPAL BROADEN	Arthritis, Psoriatic	Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3 At end of Month 3	Adalimumab, 40 mg, Every 2 Weeks	51.89 Percentage or participants
			Placebo	33.33 Percentage or participants
			Tofacitinib, 10 mg, Twice Daily	60.58 Percentage or participants
			Tofacitinib, 5 mg, Twice Daily	50.47 Percentage or participants
NCT01882439 OPAL BEYOND	Arthritis, Psoriatic	Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3 Month 3	Placebo	-0.1391 Units on a scale (±0.04573 Standard Error)
			Tofacitinib, 10 mg, Twice Daily	-0.3540 Units on a scale (±0.04579 Standard Error)
			Tofacitinib, 5 mg Twice Daily	-0.3920 Units on a scale (±0.04544 Standard Error)
NCT01882439 OPAL BEYOND	Arthritis, Psoriatic	Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 Month 3	Placebo	23.66 Percentage of participants
			Tofacitinib, 10 mg, Twice Daily	46.97 Percentage of participants
			Tofacitinib, 5 mg Twice Daily	49.62 Percentage of participants
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic	Number of Adverse Events (AEs) by Severity Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)	All Participants	1632 adverse events
			All Participants	1045 adverse events
			All Participants	136 adverse events
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic	Number of Participants With Abnormal Clinical Laboratory Values Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)	All Participants	646 Participants
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic	Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values Date of first dose of study medication (Baseline) up to 48 months (36 months of main study and 12 months of sub-study)	All Participants	9 Participants
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)	All Participants	83.7 percentage of participants
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic		All Participants	16.8 percentage of participants
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic	Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6 Sub-study: Baseline (Day 1), Month 6	Tofacitinib 5 mg BID + Methotrexate (MTX)	0.0174 units on a scale (±0.02775 Standard Error)
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic		Tofacitinib 5 mg BID + Placebo	0.0428 units on a scale (±0.02714 Standard Error)
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic	Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 Sub-study: Baseline (Day 1), Month 6	Tofacitinib 5 mg BID + Methotrexate (MTX)	0.138 units on a scale (±0.0805 Standard Error)
NCT01976364 OPAL BALANCE	Arthritis, Psoriatic		Tofacitinib 5 mg BID + Placebo	0.229 units on a scale (±0.0786 Standard Error)
NCT02281552	Arthritis, Rheumatoid	Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12 Baseline, Week 12	Tofacitinib Immediate Release (IR)	-2.85 units on a scale (±0.09 Standard Error)
NCT02281552	Arthritis, Rheumatoid		Tofacitinib Modified Release (MR)	-2.43 units on a scale (±0.09 Standard Error)
NCT02592434	Arthritis, Juvenile	Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44 Week 44	Placebo	52.86 percentage of participants
NCT02592434	Arthritis, Juvenile		Tofacitinib: Double Blind Phase	29.17 percentage of participants
NCT03000439	Arthritis, Juvenile	Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase From randomization up to 248 weeks	Placebo DB	295.0 Days
NCT03000439	Arthritis, Juvenile		Tofacitinib 5mg BID DB	NA Days
NCT03486457	Arthritis, Psoriatic	Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 3 Month 3	Placebo Then Tofacitinib	5.88 Percentage of participants
NCT03486457	Arthritis, Psoriatic		Tofacitinib	38.24 Percentage of participants
NCT03502616	Spondylitis, Ankylosing	Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16 Week 16	Placebo Then Tofacitinib	29.41 Percentage of participants
NCT03502616	Spondylitis, Ankylosing		Tofacitinib	56.39 Percentage of participants
NCT03970837 contRAst 2	Arthritis, Rheumatoid	Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 (Asia Cohort) Week 12	GSK3196165 150mg + csDMARD (Asia Cohort)	40.0 Percentage of participants
			GSK3196165 90mg + csDMARD (Asia Cohort)	45.0 Percentage of participants
			Pooled Placebo (Asia Cohort)	14.0 Percentage of participants
			Tofacitinib 5mg + csDMARD (Asia Cohort)	68.0 Percentage of participants
NCT03970837 contRAst 2	Arthritis, Rheumatoid	Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo (Global Cohort) Week 12	GSK3196165 150mg + csDMARD (Global Cohort)	54.5 Percentage of participants
			GSK3196165 90mg + csDMARD (Global Cohort)	54.9 Percentage of participants
			Pooled Placebo (Global Cohort)	32.5 Percentage of participants
			Tofacitinib 5mg + csDMARD (Global Cohort)	71.1 Percentage of participants
NCT03980483 contRAst 1	Arthritis, Rheumatoid	Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo Week 12	GSK3196165 150mg + MTX	50.9 Percentage of participants
			GSK3196165 90mg + MTX	54.7 Percentage of participants
			Pooled Placebo	42.7 Percentage of participants
			Tofacitinib 5mg + MTX	63.6 Percentage of participants

Publications by year

1973–2026: 448 publications.

1973

1976

1987

1991

1994

1996

1997

1998

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Publications by indication

Colitis, Ulcerative (181)

Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.
Ther Adv Gastroenterol · 2025 · PMID 40535533 · NCT04338204
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program.
Ther Adv Gastroenterol · 2024 · PMID 36506749 · NCT01458951
Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.
Crohns Colitis 360 · 2024 · PMID 38425446 · NCT01458951
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
United European Gastroenterol J · 2024 · PMID 38778549 · NCT01458951
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Inflamm Bowel Dis · 2023 · PMID 35648151 · NCT01458951

Arthritis, Psoriatic (63)

Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials.
Rheumatol Ther · 2025 · PMID 41148555 · NCT01976364
Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis.
Rheumatol Adv Pract · 2025 · PMID 40241921 · NCT01877668
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.
RMD Open · 2025 · PMID 40461265 · NCT01877668
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
Rheumatol Ther · 2024 · PMID 34870800 · NCT01882439
Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
ACR Open Rheumatol · 2024 · PMID 32910531 · NCT01882439

Arthritis, Rheumatoid (45)

Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA).
BMJ Open · 2026 · PMID 41689213 · NCT03387423
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.
Ann Rheum Dis · 2026 · PMID 40992967 · NCT02092467
Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy.
Rheumatology (Oxford) · 2026 · PMID 41025512 · NCT04449224
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.
Rheumatol Ther · 2025 · PMID 39060905 · NCT02092467
Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
J Autoimmun · 2024 · PMID 39146891 · NCT06979271

Alopecia Areata (27)

JAK inhibition decreases the autoimmune burden in Down syndrome.
medRxiv · 2025 · PMID 38946973 · NCT04246372
JAAD Game Changers: Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
J Am Acad Dermatol · 2024 · PMID 38823686 · NCT07101471
JAK inhibition decreases the autoimmune burden in Down syndrome.
Elife · 2024 · PMID 39737640 · NCT04246372
Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Indian Dermatol Online J · 2023 · PMID 37521227 · NCT06278402
Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
Acta Derm Venereol · 2023 · PMID 37955531 · NCT06278402

Lichen Planus (26)

Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia · 2024 · PMID 30085543 · NCT06202560
Clinicopathological Features of Alopecia With an Emphasis on Etiology and Histopathological Characteristics of Scarring Alopecia.
Cureus · 2022 · PMID 36072194 · NCT06202560
Frontal fibrosing alopecia.
Clin Dermatol · 2021 · PMID 34272007 · NCT06202560
Tofacitinib for the treatment of lichen planopilaris: A case series.
Dermatol Ther · 2019 · PMID 30264512 · NCT06202560
Medical therapy for frontal fibrosing alopecia: A review and clinical approach.
J Am Acad Dermatol · 2019 · PMID 30953702 · NCT06202560

Spondylarthritis (19)

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.
Rheumatol Ther · 2025 · PMID 39636343 · NCT01786668
Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two Trials.
Arthritis Care Res (Hoboken) · 2024 · PMID 37909386 · NCT01786668
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials.
J Rheumatol · 2024 · PMID 38825359 · NCT01786668
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.
Adv Rheumatol · 2024 · PMID 39695887 · NCT01786668
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.
Rheumatol Ther · 2023 · PMID 37331992 · NCT01786668

Publications by journal

Ann Rheum Dis34 papers
Inflamm Bowel Dis17 papers
Rheumatol Ther16 papers
N Engl J Med14 papers
RMD Open14 papers
J Crohns Colitis14 papers
Arthritis Res Ther12 papers
J Am Acad Dermatol10 papers
Gastroenterology10 papers
Rheumatology (Oxford)10 papers

Trial-results highlights

In studies for ulcerative colitis, the percentage of participants achieving remission at Week 8 was assessed. In NCT01458951, Tofacitinib 10 mg BID resulted in 16.6 percentage of participants achieving remission at Week 8. In the same study, the placebo BID arm reported 3.6 percentage of participants achieving remission at Week 8. Another study, NCT01465763, reported that 18.5 percentage of participants in the Tofacitinib 10 mg BID arm achieved remission at Week 8, while 8.2 percentage of participants in the placebo BID arm achieved remission at Week 8.

For juvenile arthritis, an open-label study, NCT01500551, evaluated body weight in participants receiving Tofacitinib 5 mg BID. The mean absolute body weight and its mean change from baseline were observed over several time points:

At Month 12, the mean absolute body weight was 49.16 Kilograms, with a mean change from baseline of 6.52 Kilograms.
At Month 24, the mean absolute body weight was 52.42 Kilograms, with a mean change from baseline of 9.42 Kilograms.
At Month 36, the mean absolute body weight was 56.96 Kilograms, with a mean change from baseline of 12.44 Kilograms.
At Month 48, the mean absolute body weight was 56.72 Kilograms, with a mean change from baseline of 13.99 Kilograms.
At Month 60, the mean absolute body weight was 58.07 Kilograms, with a mean change from baseline of 17.50 Kilograms.
At Month 72, the mean absolute body weight was 58.38 Kilograms, with a mean change from baseline of 20.55 Kilograms.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Tofacitinib publications (448)

2026 (6 papers)

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.
Takeuchi T, Tanaka Y, Yamanaka H, et al. · Rheumatol Ther · 2026 · Derived
PubMed: PMID 41565911 · NCT02187055 (ORAL STRATEGY)
Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA).
Krueger K, Behrens F, Brandt-Juergens J, et al. · BMJ Open · 2026 · Derived
PubMed: PMID 41689213 · NCT03387423 (ESCALATE-RA) · Arthritis, Rheumatoid
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.
Giles JT, Charles-Schoeman C, Buch MH, et al. · Ann Rheum Dis · 2026 · Derived
PubMed: PMID 40992967 · NCT02092467 · Arthritis, Rheumatoid
Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy.
Cho SK, Choi SR, Nam E, et al. · Rheumatology (Oxford) · 2026 · Derived
PubMed: PMID 41025512 · NCT04449224 · Arthritis, Rheumatoid
Efficacy and Safety of Tofacitinib Compared to Cyclophosphamide in Early Diffuse Cutaneous Systemic Sclerosis: A Randomized Controlled Trial.
Amin Khan N, Islam A, Shahin A, et al. · Cureus · 2026 · Derived
PubMed: PMID 41809291 · NCT06044844
Tofacitinib for Refractory Thyroid Eye Disease.
Ghahvehchian H, Eshraghi B · JAMA Ophthalmol · 2026 · Background
PubMed: PMID 41165674 · NCT07547930 (TOFA-GO) · Graves Ophthalmopathy

2025 (18 papers)

Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model.
Zhang X, Jia L, Lin X, et al. · Immunology · 2025 · Derived
PubMed: PMID 41039829 · NCT03502616 · Spondylitis, Ankylosing
Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
Wright GC, Mysler E, Kwok K, et al. · Rheumatol Ther · 2025 · Derived
PubMed: PMID 38958913 · NCT02187055 (ORAL STRATEGY)
Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE.
Rios Rodriguez V, Sánchez-Riera L, Haibel H, et al. · Ther Adv Musculoskelet Dis · 2025 · Derived
PubMed: PMID 40078463 · NCT06112665 (FASTLANE) · Axial Spondyloarthritis
JAK inhibition decreases the autoimmune burden in Down syndrome.
Rachubinski AL, Wallace E, Gurnee E, et al. · medRxiv · 2025 · Derived
PubMed: PMID 38946973 · NCT04246372 · Alopecia Areata
Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.
Nyberg L, Halfvarson J, Söderling J, et al. · Ther Adv Gastroenterol · 2025 · Derived
PubMed: PMID 40535533 · NCT04338204 (ODEN) · Colitis, Ulcerative
Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.
Norton H, Sliwinska-Stanczyk P, Hala T, et al. · Rheumatol Ther · 2025 · Derived
PubMed: PMID 39636343 · NCT01786668 · Spondylarthritis
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study).
Narula N, Pray C, Hamam H, et al. · Crohns Colitis 360 · 2025 · Derived
PubMed: PMID 40092634 · NCT04925973 (TRIUMPH)
Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment.
Liu Q, Zeng Y, Xing X, et al. · Rheumatology (Oxford) · 2025 · Derived
PubMed: PMID 40139690 · NCT05087589
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
Kristensen LE, Deodhar A, Leung YY, et al. · Rheumatol Ther · 2025 · Derived
PubMed: PMID 38696034 · NCT03502616 · Spondylitis, Ankylosing
Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China.
Hu Y, Li P, Liu J, et al. · J Rheumatol · 2025 · Derived
PubMed: PMID 40233998 · NCT06688838 (inapplicable) · Blau syndrome
Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial.
Gossec L, Walsh JA, Sengupta R, et al. · Rheumatol Ther · 2025 · Derived
PubMed: PMID 39671076 · NCT03502616 · Spondylitis, Ankylosing
Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials.
Gossec L, Sellas A, Gruben DC, et al. · Rheumatol Ther · 2025 · Derived
PubMed: PMID 41148555 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis.
Gladman DD, Dougados M, Marzo-Ortega H, et al. · Rheumatol Adv Pract · 2025 · Derived
PubMed: PMID 40241921 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.
Gladman D, Tillett W, Gruben D, et al. · RMD Open · 2025 · Derived
PubMed: PMID 40461265 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.
Consolaro A, Ruperto N, Lovell DJ, et al. · J Rheumatol · 2025 · Derived
PubMed: PMID 40312101 · NCT02592434 · Arthritis, Juvenile
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.
Batko B, Jeka S, Wiland P, et al. · Rheumatol Ther · 2025 · Derived
PubMed: PMID 39060905 · NCT02092467 · Arthritis, Rheumatoid
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.
Wiersinga WM, Eckstein AK, Žarković M, et al. · Lancet Diabetes Endocrinol · 2025 · Background
PubMed: PMID 40324443 · NCT07547930 (TOFA-GO) · Graves Ophthalmopathy
Role of the suppressor of cytokine signaling-3 in the pathogenesis of Graves' orbitopathy.
Kim W, Seo MK, Kim YJ, et al. · Front Endocrinol (Lausanne) · 2025 · Background
PubMed: PMID 40104138 · NCT07547930 (TOFA-GO) · Graves Ophthalmopathy

2024 (34 papers)

Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
Zeng L, Yang K, Wu Y, et al. · J Autoimmun · 2024 · Trial result
PubMed: PMID 39146891 · NCT06979271 · Arthritis, Rheumatoid
JAAD Game Changers: Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Wohltmann WE · J Am Acad Dermatol · 2024 · Trial result
PubMed: PMID 38823686 · NCT07101471 · Alopecia Areata
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
Winthrop KL, Curtis JR, Yamaoka K, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 34870800 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N, Peer CJ, Zhang X, et al. · Front Oncol · 2024 · Derived
PubMed: PMID 38706610 · NCT04034238 · Adenocarcinoma
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program.
Sandborn WJ, Sands BE, Vermeire S, et al. · Ther Adv Gastroenterol · 2024 · Derived
PubMed: PMID 36506749 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.
Rubin DT, Torres J, Regueiro M, et al. · Crohns Colitis 360 · 2024 · Derived
PubMed: PMID 38425446 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
Ritchlin CT, Giles JT, Ogdie A, et al. · ACR Open Rheumatol · 2024 · Derived
PubMed: PMID 32910531 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
JAK inhibition decreases the autoimmune burden in Down syndrome.
Rachubinski AL, Wallace E, Gurnee E, et al. · Elife · 2024 · Derived
PubMed: PMID 39737640 · NCT04246372 · Alopecia Areata
Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention.
Pope J, Finckh A, Silva-Fernández L, et al. · Open Access Rheumatol · 2024 · Derived
PubMed: PMID 38883150 · NCT02187055 (ORAL STRATEGY)
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
Panés J, D'Haens GR, Sands BE, et al. · United European Gastroenterol J · 2024 · Derived
PubMed: PMID 38778549 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
Orbai AM, Mease PJ, Helliwell PS, et al. · BMC Rheumatol · 2024 · Derived
PubMed: PMID 36045453 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status.
Ogdie A, Kristensen LE, Soriano ER, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 39320582 · NCT03502616 · Spondylitis, Ankylosing
Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis.
Navarro-Compán V, Deodhar A, Bahiri R, et al. · Arthritis Res Ther · 2024 · Derived
PubMed: PMID 38790040 · NCT03502616 · Spondylitis, Ankylosing
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Nash P, Mease PJ, Fleishaker D, et al. · Lancet Rheumatol · 2024 · Derived
PubMed: PMID 38273637 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Nash P, Coates LC, Fleishaker D, et al. · Lancet Rheumatol · 2024 · Derived
PubMed: PMID 38279411 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two Trials.
Magrey M, Wei JC, Yndestad A, et al. · Arthritis Care Res (Hoboken) · 2024 · Derived
PubMed: PMID 37909386 · NCT01786668 · Spondylarthritis
A Phase I, Randomized, Multi-Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants.
Ma X, Borzillo G, Kothe MJC, et al. · Clin Pharmacol Ther · 2024 · Derived
PubMed: PMID 38159266 · NCT04552197
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Kuwana M, Sugiyama N, Momohara S, et al. · Mod Rheumatol · 2024 · Derived
PubMed: PMID 37405710 · NCT01932372 · Arthritis, Rheumatoid
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib.
Hetland ML, Strangfeld A, Bonfanti G, et al. · Arthritis Res Ther · 2024 · Derived
PubMed: PMID 39192350 · NCT02187055 (ORAL STRATEGY)
Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial.
Guimarães PO, Damiani LP, Tavares CAM, et al. · Einstein (Sao Paulo) · 2024 · Derived
PubMed: PMID 39504090 · NCT04469114 · COVID-19
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis.
Gladman DD, Nash P, Mease PJ, et al. · Arthritis Res Ther · 2024 · Derived
PubMed: PMID 39702318 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
Dikranian A, Gold D, Bessette L, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 34921355 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials.
Deodhar A, Baraliakos X, Magrey M, et al. · J Rheumatol · 2024 · Derived
PubMed: PMID 38825359 · NCT01786668 · Spondylarthritis
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.
Deodhar A, Akar S, Curtis JR, et al. · Adv Rheumatol · 2024 · Derived
PubMed: PMID 39695887 · NCT01786668 · Spondylarthritis
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.
de Vlam K, Mease PJ, Bushmakin AG, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 36076054 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study.
Citera G, Mysler E, Kakehasi AM, et al. · J Clin Rheumatol · 2024 · Derived
PubMed: PMID 38880956 · NCT02092467 · Arthritis, Rheumatoid
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
Citera G, Jain R, Irazoque F, et al. · Rheumatol Ther · 2024 · Derived
PubMed: PMID 37925660 · NCT02187055 (ORAL STRATEGY)
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis.
Chang C, Vong C, Wang X, et al. · CPT Pharmacometrics Syst Pharmacol · 2024 · Derived
PubMed: PMID 38298058 · NCT02592434 · Arthritis, Juvenile
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
Buch MH, Bhatt DL, Charles-Schoeman C, et al. · RMD Open · 2024 · Derived
PubMed: PMID 38609322 · NCT02092467 · Arthritis, Rheumatoid
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.
Brunner HI, Akikusa JD, Al-Abadi E, et al. · Ann Rheum Dis · 2024 · Derived
PubMed: PMID 38849152 · NCT01500551 · Arthritis, Juvenile
Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia · 2024 · Background
PubMed: PMID 30085543 · NCT06202560 (Tofacitinib) · Lichen Planus
JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle.
Shrager JB, Randle R, Lee M, et al. · Life Sci Alliance · 2024 · Background
PubMed: PMID 39122555 · NCT03681275
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.
Dejaco C, Kerschbaumer A, Aletaha D, et al. · Ann Rheum Dis · 2024 · Background
PubMed: PMID 36828585 · NCT06172361 (ITTGPMR) · Polymyalgia Rheumatica
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.
Ashour HM, Elkhatib WF, Rahman MM, et al. · Pathogens · 2024 · Background
PubMed: PMID 32143502 · NCT04332042

2023 (40 papers)

Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K, Bathula S, Khurana A, et al. · Indian Dermatol Online J · 2023 · Trial result
PubMed: PMID 37521227 · NCT06278402 · Alopecia Areata
Treatment trends in oral lichen planus and oral lichenoid lesions (Review).
Rotaru D, Chisnoiu R, Picos AM, et al. · Exp Ther Med · 2023 · Trial result
PubMed: PMID 33123228 · NCT07131813 · Lichen Planus, Oral
CD8+ tissue-resident memory T cells induce oral lichen planus erosion via cytokine network.
Qing M, Yang D, Shang Q, et al. · Elife · 2023 · Trial result
PubMed: PMID 37555396 · NCT07131813 · Lichen Planus, Oral
Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
Huang J, Deng S, Li J, et al. · Acta Derm Venereol · 2023 · Trial result
PubMed: PMID 37955531 · NCT06278402 · Alopecia Areata
Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis.
Gupta AK, Carviel JL, Foley KA, et al. · Skin Appendage Disord · 2023 · Trial result
PubMed: PMID 31799258 · NCT06278402 · Alopecia Areata
The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions.
Donovan J · Skin Therapy Lett · 2023 · Trial result
PubMed: PMID 37339501 · NCT06278402 · Alopecia Areata
Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study.
Zhang L, Li J, Yin H, et al. · Ann Rheum Dis · 2023 · Derived
PubMed: PMID 36604153 · NCT04799262 · Polymyalgia Rheumatica
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Winthrop KL, Yndestad A, Henrohn D, et al. · Rheumatol Ther · 2023 · Derived
PubMed: PMID 36526796 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL, Vermeire S, Long MD, et al. · Inflamm Bowel Dis · 2023 · Derived
PubMed: PMID 35648151 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
Targownik L, Dubinsky MC, Steinwurz F, et al. · J Crohns Colitis · 2023 · Derived
PubMed: PMID 36271912 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
Schreiber S, Rubin DT, Ng SC, et al. · J Crohns Colitis · 2023 · Derived
PubMed: PMID 37402275 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE, Citera G, Nash P, et al. · Semin Arthritis Rheum · 2023 · Derived
PubMed: PMID 36476498 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ, D'Haens GR, Sands BE, et al. · J Crohns Colitis · 2023 · Derived
PubMed: PMID 36124702 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program.
Rubin DT, Salese L, Cohen M, et al. · Ther Adv Gastroenterol · 2023 · Derived
PubMed: PMID 37560161 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.
Rubin DT, Reinisch W, Greuter T, et al. · Ther Adv Gastroenterol · 2023 · Derived
PubMed: PMID 34035832 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.
Østergaard M, Wu J, Fallon L, et al. · Rheumatol Ther · 2023 · Derived
PubMed: PMID 37331992 · NCT01786668 · Spondylarthritis
Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Mease PJ, Orbai AM, FitzGerald O, et al. · Arthritis Res Ther · 2023 · Derived
PubMed: PMID 37608391 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
Loftus EV, Baumgart DC, Gecse K, et al. · Inflamm Bowel Dis · 2023 · Derived
PubMed: PMID 35792493 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Lichtenstein GR, Cohen BL, Salese L, et al. · Dig Dis Sci · 2023 · Derived
PubMed: PMID 36739367 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR, Bressler B, Francisconi C, et al. · Inflamm Bowel Dis · 2023 · Derived
PubMed: PMID 36342120 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
Leng X, Lin W, Liu S, et al. · RMD Open · 2023 · Derived
PubMed: PMID 36720560 · NCT03486457 · Arthritis, Psoriatic
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE, Danese S, Yndestad A, et al. · Ann Rheum Dis · 2023 · Derived
PubMed: PMID 36931693 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
Khan MM, Ahmed S, Hasan Sajib MK, et al. · Int J Rheum Dis · 2023 · Derived
PubMed: PMID 37377385 · NCT04464642 · Arthritis, Rheumatoid
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.
Karpouzas GA, Szekanecz Z, Baecklund E, et al. · Ther Adv Musculoskelet Dis · 2023 · Derived
PubMed: PMID 37942277 · NCT02092467 · Arthritis, Rheumatoid
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
Hudesman DP, Torres J, Salese L, et al. · Patient · 2023 · Derived
PubMed: PMID 36336750 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
Hansen KE, Mortezavi M, Nagy E, et al. · Ther Adv Musculoskelet Dis · 2023 · Derived
PubMed: PMID 36601090 · NCT02281552 · Arthritis, Rheumatoid
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Fleischmann RM, van der Heijde D, Strand V, et al. · Ann Rheum Dis · 2023 · Derived
PubMed: PMID 37699654 · NCT03970837 (contRAst 2) · Arthritis, Rheumatoid
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
Eder L, Gladman DD, Mease P, et al. · RMD Open · 2023 · Derived
PubMed: PMID 36958766 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
Dubinsky MC, Magro F, Steinwurz F, et al. · Inflamm Bowel Dis · 2023 · Derived
PubMed: PMID 35380664 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
Dubinsky MC, Armuzzi A, Gecse KB, et al. · Dig Dis · 2023 · Derived
PubMed: PMID 36603566 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
Dougados M, Taylor PC, Bingham CO, et al. · RMD Open · 2023 · Derived
PubMed: PMID 36814062 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Curtis JR, Yamaoka K, Chen YH, et al. · Ann Rheum Dis · 2023 · Derived
PubMed: PMID 36600185 · NCT02147587 · Arthritis, Rheumatoid
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Charles-Schoeman C, Buch MH, Dougados M, et al. · Ann Rheum Dis · 2023 · Derived
PubMed: PMID 36137735 · NCT02092467 · Arthritis, Rheumatoid
Prevalence of musculoskeletal conditions and related disabilities in Bangladeshi adults: a cross-sectional national survey.
Zahid-Al-Quadir A, Zaman MM, Ahmed S, et al. · BMC Rheumatol · 2023 · Background
PubMed: PMID 33323124 · NCT06114407 · Spondylarthritis
First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
PubMed: PMID 35129472 · NCT07352566 · Psoriasis
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib.
Spinelli FR, Garufi C, Mancuso S, et al. · Sci Rep · 2023 · Background
PubMed: PMID 37730835 · NCT06172361 (ITTGPMR) · Polymyalgia Rheumatica
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
Ramiro S, Nikiphorou E, Sepriano A, et al. · Ann Rheum Dis · 2023 · Background
PubMed: PMID 36270658 · NCT06114407 · Spondylarthritis
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
PubMed: PMID 37672566 · NCT07352566 · Psoriasis
Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.
Ma X, Yang F, Wu J, et al. · PLoS Med · 2023 · Background
PubMed: PMID 37384596 · NCT06172361 (ITTGPMR) · Polymyalgia Rheumatica
A genome-scale CRISPR tool for targeting multiple gene family members at once.
Nat Plants · 2023 · Background
PubMed: PMID 36973416 · NCT07297069

2022 (40 papers)

Oral lichen planus: comparative efficacy and treatment costs-a systematic review.
Sandhu S, Klein BA, Al-Hadlaq M, et al. · BMC Oral Health · 2022 · Trial result
PubMed: PMID 35524296 · NCT07131813 · Lichen Planus, Oral
Stimulatory Effect of Tofacitinib on Bone Marrow Adipocytes Differentiation.
Letarouilly JG, Paccou J, Badr S, et al. · Front Endocrinol (Lausanne) · 2022 · Trial result
PubMed: PMID 35873000 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis.
Kulkarni S, Durham H, Glover L, et al. · BMJ Open · 2022 · Trial result
PubMed: PMID 36549729 · NCT07131813 · Lichen Planus, Oral
Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H, Abdulla N, Al-Obaidli A, et al. · Dermatol Ther · 2022 · Trial result
PubMed: PMID 36177791 · NCT06278402 · Alopecia Areata
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
Fleischmann R, Wollenhaupt J, Takiya L, et al. · RMD Open · 2022 · Trial result
PubMed: PMID 29435359 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. · N Engl J Med · 2022 · Derived
PubMed: PMID 35081280 · NCT02092467 · Arthritis, Rheumatoid
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Weitz JI, Szekanecz Z, Charles-Schoeman C, et al. · RMD Open · 2022 · Derived
PubMed: PMID 36323490 · NCT02092467 · Arthritis, Rheumatoid
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies.
Taylor PC, Bushmakin AG, Cappelleri JC, et al. · J Dermatolog Treat · 2022 · Derived
PubMed: PMID 35385361 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Sands BE, Colombel JF, Ha C, et al. · Inflamm Bowel Dis · 2022 · Derived
PubMed: PMID 32870265 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ, Peyrin-Biroulet L, Sharara AI, et al. · Clin Gastroenterol Hepatol · 2022 · Derived
PubMed: PMID 33684552 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. · Clin Gastroenterol Hepatol · 2022 · Derived
PubMed: PMID 33127596 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N, Brunner HI, Synoverska O, et al. · Lancet · 2022 · Derived
PubMed: PMID 34767764 · NCT02592434 · Arthritis, Juvenile
Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis.
Razmjou AA, Brook J, Elashoff D, et al. · BMC Rheumatol · 2022 · Derived
PubMed: PMID 33089069 · NCT02321930 · Arthritis, Rheumatoid
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
Navarro-Compán V, Wei JC, Van den Bosch F, et al. · RMD Open · 2022 · Derived
PubMed: PMID 35654457 · NCT03502616 · Spondylitis, Ankylosing
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Mukherjee A, Tsuchiwata S, Nicholas T, et al. · Clin Pharmacol Ther · 2022 · Derived
PubMed: PMID 35380740 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
Motoya S, Watanabe M, Kim HJ, et al. · Intest Res · 2022 · Derived
PubMed: PMID 29743836 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR, Rogler G, Ciorba MA, et al. · Inflamm Bowel Dis · 2022 · Derived
PubMed: PMID 32766762 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Janus kinase inhibitors for the treatment of COVID-19.
Kramer A, Prinz C, Fichtner F, et al. · Cochrane Database Syst Rev · 2022 · Derived
PubMed: PMID 35695334 · NCT04469114 · COVID-19
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ, FitzGerald O, Nash P, et al. · Clin Rheumatol · 2022 · Derived
PubMed: PMID 34510295 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
Khosrow-Khavar F, Kim SC, Lee H, et al. · Ann Rheum Dis · 2022 · Derived
PubMed: PMID 35027405 · NCT04772248 · Arthritis, Rheumatoid
Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.
Khosrow-Khavar F, Desai RJ, Lee H, et al. · Arthritis Rheumatol · 2022 · Derived
PubMed: PMID 35643956 · NCT04798287 (STAR-RA-Cancer) · Arthritis, Rheumatoid
Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
Khanna D, Padilla C, Tsoi LC, et al. · JCI Insight · 2022 · Derived
PubMed: PMID 35943798 · NCT03274076 (TOFA-SSc) · Scleroderma, Systemic
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
Gladman DD, Coates LC, Wu J, et al. · Arthritis Res Ther · 2022 · Derived
PubMed: PMID 35139908 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
Dubinsky MC, DiBonaventura M, Fan H, et al. · Inflamm Bowel Dis · 2022 · Derived
PubMed: PMID 32794567 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. · Ann Rheum Dis · 2022 · Derived
PubMed: PMID 33906853 · NCT03502616 · Spondylitis, Ankylosing
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.
Damsky W, Wang A, Kim DJ, et al. · Nat Commun · 2022 · Derived
PubMed: PMID 35668129 · NCT03910543 · Granuloma Annulare
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
Curtis JR, Regueiro M, Yun H, et al. · Inflamm Bowel Dis · 2022 · Derived
PubMed: PMID 33324993 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Ultrasound detects synovitis in replaced and other surgically operated joints in rheumatoid arthritis patients.
Choate EA, Kaeley GS, Brook J, et al. · BMC Rheumatol · 2022 · Derived
PubMed: PMID 32025629 · NCT02321930 · Arthritis, Rheumatoid
Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis.
Cella D, Lenderking WR, Chongpinitchai P, et al. · J Patient Rep Outcomes · 2022 · Derived
PubMed: PMID 36138330 · NCT01786668 · Spondylarthritis
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
Bessette L, Mysler E, Kinch CD, et al. · J Rheumatol · 2022 · Derived
PubMed: PMID 35232809 · NCT02187055 (ORAL STRATEGY)
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Balanescu AR, Citera G, Pascual-Ramos V, et al. · Ann Rheum Dis · 2022 · Derived
PubMed: PMID 35922124 · NCT02092467 · Arthritis, Rheumatoid
The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights.
Toussirot E · Pharmaceuticals (Basel) · 2022 · Background
PubMed: PMID 35337068 · NCT06114407 · Spondylarthritis
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
PubMed: PMID 35788566 · NCT07352566 · Psoriasis
Rationale and design of a mechanistic clinical trial of JAK inhibition to prevent ventilator-induced diaphragm dysfunction.
Shrager JB, Wang Y, Lee M, et al. · Respir Med · 2022 · Background
PubMed: PMID 34655959 · NCT03681275
Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
Lee SH, Walshe M, Oh EH, et al. · Inflamm Bowel Dis · 2022 · Background
PubMed: PMID 33269403 · NCT05186623 · Colitis, Ulcerative
Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J, Yoon H, Kim N, et al. · Inflamm Bowel Dis · 2022 · Background
PubMed: PMID 33501935 · NCT05186623 · Colitis, Ulcerative
Clinicopathological Features of Alopecia With an Emphasis on Etiology and Histopathological Characteristics of Scarring Alopecia.
Hashmi AA, Rashid K, Ali R, et al. · Cureus · 2022 · Background
PubMed: PMID 36072194 · NCT06202560 (Tofacitinib) · Lichen Planus
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles.
Fuchs F, Schillinger D, Atreya R, et al. · Front Immunol · 2022 · Background
PubMed: PMID 28717358 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. · JAMA · 2022 · Background
PubMed: PMID 36125471 · NCT06172361 (ITTGPMR) · Polymyalgia Rheumatica
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
Chaparro M, Barreiro-de Acosta M, Benítez JM, et al. · Ther Adv Gastroenterol · 2022 · Background
PubMed: PMID 31205485 · NCT05313620 · Colitis, Ulcerative

2021 (32 papers)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).
Konstantinides SV, Meyer G, Becattini C, et al. · Eur Heart J · 2021 · Trial result
PubMed: PMID 31504429 · NCT04624230 · Colitis, Ulcerative
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease.
Kelsen JR, Sullivan KE, Rabizadeh S, et al. · J Pediatr Gastroenterol Nutr · 2021 · Trial result
PubMed: PMID 32079889 · NCT04624230 · Colitis, Ulcerative
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Dillon KL · Clin Cosmet Investig Dermatol · 2021 · Trial result
PubMed: PMID 34211288 · NCT06278402 · Alopecia Areata
Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib.
Wang A, Rahman NT, McGeary MK, et al. · J Allergy Clin Immunol · 2021 · Derived
PubMed: PMID 33317858 · NCT03910543 · Granuloma Annulare
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Vong C, Martin SW, Deng C, et al. · Clin Pharmacol Drug Dev · 2021 · Derived
PubMed: PMID 33513294 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
van der Heijde D, Landewé RBM, Wollenhaupt J, et al. · Rheumatology (Oxford) · 2021 · Derived
PubMed: PMID 33057725 · NCT01164579 · Arthritis, Rheumatoid
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Takeuchi T, Fleischmann R, Iikuni N, et al. · Arthritis Res Ther · 2021 · Derived
PubMed: PMID 34429160 · NCT02187055 (ORAL STRATEGY)
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE, Taub PR, Armuzzi A, et al. · Clin Gastroenterol Hepatol · 2021 · Derived
PubMed: PMID 31077827 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial.
Proft F, Torgutalp M, Muche B, et al. · BMJ Open · 2021 · Derived
PubMed: PMID 34785545 · NCT04062695 (PASTOR) · Arthritis, Psoriatic
Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R, Isaacs JD, Chen LA, et al. · Dig Dis Sci · 2021 · Derived
PubMed: PMID 32816215 · NCT01710046
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
Paik JJ, Casciola-Rosen L, Shin JY, et al. · Arthritis Rheumatol · 2021 · Derived
PubMed: PMID 33258553 · NCT03002649 (STIR) · Dermatomyositis
The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks.
Kim SK, Jung UH, Kim JW, et al. · Medicine (Baltimore) · 2021 · Derived
PubMed: PMID 34397713 · NCT02321930 · Arthritis, Rheumatoid
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Hasni SA, Gupta S, Davis M, et al. · Nat Commun · 2021 · Derived
PubMed: PMID 34099646 · NCT02535689 · Lupus Erythematosus, Systemic
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
Guimarães PO, Quirk D, Furtado RH, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 34133856 · NCT04469114 · COVID-19
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
Friedman MA, Le B, Stevens J, et al. · Lung · 2021 · Derived
PubMed: PMID 33825964 · NCT03793439 · Sarcoidosis
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
Feagan BG, Khanna R, Sandborn WJ, et al. · Aliment Pharmacol Ther · 2021 · Derived
PubMed: PMID 34614208 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Farraye FA, Qazi T, Kotze PG, et al. · Aliment Pharmacol Ther · 2021 · Derived
PubMed: PMID 34165201 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.
de Vlam K, Ogdie A, Bushmakin AG, et al. · RMD Open · 2021 · Derived
PubMed: PMID 34226183 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB, Tanaka Y, Mariette X, et al. · RMD Open · 2021 · Derived
PubMed: PMID 33127856 · NCT02147587 · Arthritis, Rheumatoid
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib.
Coates LC, Bushmakin AG, FitzGerald O, et al. · Arthritis Res Ther · 2021 · Derived
PubMed: PMID 33766074 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Burmester GR, Curtis JR, Yun H, et al. · Drug Saf · 2021 · Derived
PubMed: PMID 32006348 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis.
Vacchi C, Manfredi A, Cassone G, et al. · Case Rep Med · 2021 · Background
PubMed: PMID 33976699 · NCT05246293 (RAILDTo) · Arthritis, Rheumatoid
JAK inhibition for treatment of psoriatic arthritis in Down syndrome.
Pham AT, Rachubinski AL, Enriquez-Estrada B, et al. · Rheumatology (Oxford) · 2021 · Background
PubMed: PMID 33630031 · NCT04246372 · Alopecia Areata
Frontal fibrosing alopecia.
Kerkemeyer KLS, Eisman S, Bhoyrul B, et al. · Clin Dermatol · 2021 · Background
PubMed: PMID 34272007 · NCT06202560 (Tofacitinib) · Lichen Planus
An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation.
Gurbel PA, Bliden K, Barnett SD, et al. · J Cardiovasc Pharmacol Ther · 2021 · Background
PubMed: PMID 32672062 · NCT05313620 · Colitis, Ulcerative
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP, Chaparro M · J Crohns Colitis · 2021 · Background
PubMed: PMID 31777929 · NCT05313620 · Colitis, Ulcerative
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Citera G, Mysler E, Madariaga H, et al. · J Clin Rheumatol · 2021 · Background
PubMed: PMID 32826657 · NCT05246293 (RAILDTo) · Arthritis, Rheumatoid
Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel.
Cirillo P, Taglialatela V, Pellegrino G, et al. · J Thromb Thrombolysis · 2021 · Background
PubMed: PMID 32335777 · NCT05313620 · Colitis, Ulcerative
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M, Garre A, Mesonero F, et al. · J Crohns Colitis · 2021 · Background
PubMed: PMID 32969471 · NCT05313620 · Colitis, Ulcerative
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L, Kahaly GJ, Baldeschi L, et al. · Eur J Endocrinol · 2021 · Background
PubMed: PMID 34297684 · NCT07547930 (TOFA-GO) · Graves Ophthalmopathy
Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease.
Bandres-Ciga S, Saez-Atienzar S, Kim JJ, et al. · Acta Neuropathol · 2021 · Background
PubMed: PMID 32601912 · NCT05186623 · Colitis, Ulcerative
Development of a Bangla version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI).
Abdal SJ, Yesmin S, Shazzad MN, et al. · Int J Rheum Dis · 2021 · Background
PubMed: PMID 33135389 · NCT06114407 · Spondylarthritis

2020 (32 papers)

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
van der Heijde D, Gladman DD, FitzGerald O, et al. · J Rheumatol · 2020 · Derived
PubMed: PMID 30824647 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Strand V, Mysler E, Moots RJ, et al. · RMD Open · 2020 · Derived
PubMed: PMID 31673419 · NCT02187055 (ORAL STRATEGY)
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Strand V, de Vlam K, Covarrubias-Cobos JA, et al. · RMD Open · 2020 · Derived
PubMed: PMID 30713721 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Strand V, de Vlam K, Covarrubias-Cobos JA, et al. · RMD Open · 2020 · Derived
PubMed: PMID 30713722 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Sandborn WJ, Panés J, Sands BE, et al. · Aliment Pharmacol Ther · 2020 · Derived
PubMed: PMID 31599001 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Sandborn WJ, Panés J, D'Haens GR, et al. · Clin Gastroenterol Hepatol · 2020 · Derived
PubMed: PMID 30476584 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
Purohit VS, Ports WC, Wang C, et al. · J Clin Pharmacol · 2020 · Derived
PubMed: PMID 30556911 · NCT02001181 · Dermatitis, Atopic
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P, Coates LC, Kivitz AJ, et al. · Rheumatol Ther · 2020 · Derived
PubMed: PMID 32506317 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Nash P, Coates LC, Fleischmann R, et al. · Rheumatol Ther · 2020 · Derived
PubMed: PMID 30414064 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Hanauer S, Panaccione R, Danese S, et al. · Clin Gastroenterol Hepatol · 2020 · Derived
PubMed: PMID 30012431 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Gladman DD, Charles-Schoeman C, McInnes IB, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
PubMed: PMID 31112005 · NCT01976364 (OPAL BALANCE) · Arthritis, Psoriatic
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Conaghan PG, Østergaard M, Troum O, et al. · Arthritis Res Ther · 2020 · Derived
PubMed: PMID 31639034 · NCT01164579 · Arthritis, Rheumatoid
Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.
Cella D, Wilson H, Shalhoub H, et al. · J Patient Rep Outcomes · 2020 · Derived
PubMed: PMID 31111255 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.
Cella D, Wilson H, Shalhoub H, et al. · J Patient Rep Outcomes · 2020 · Derived
PubMed: PMID 30680661 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
PubMed: PMID 31207152 · NCT02187055 (ORAL STRATEGY)
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
Zumla A, Hui DS, Azhar EI, et al. · Lancet · 2020 · Background
PubMed: PMID 32035018 · NCT04332042
Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K, Nogami K, Ogiwara K, et al. · Int J Hematol · 2020 · Background
PubMed: PMID 31254165 · NCT05313620 · Colitis, Ulcerative
Effects of fibrinogen supplementation on clot formation in blood samples from cardiac surgery patients before and after tranexamic acid administration.
Waldén K, Shams Hakimi C, Jeppsson A, et al. · Transfus Med · 2020 · Background
PubMed: PMID 31115109 · NCT05313620 · Colitis, Ulcerative
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.
Tian S, Hu W, Niu L, et al. · J Thorac Oncol · 2020 · Background
PubMed: PMID 32114094 · NCT04332042
Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L, Wiendl M, Heidbreder K, et al. · Gut · 2020 · Background
PubMed: PMID 31092589 · NCT05186623 · Colitis, Ulcerative
Pharmacological enrichment of polygenic risk for precision medicine in complex disorders.
Reay WR, Atkins JR, Carr VJ, et al. · Sci Rep · 2020 · Background
PubMed: PMID 31964963 · NCT05186623 · Colitis, Ulcerative
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Rachubinski AL, Estrada BE, Norris D, et al. · JAAD Case Rep · 2020 · Background
PubMed: PMID 31008170 · NCT04246372 · Alopecia Areata
Management of venous thromboembolism: an update.
Piran S, Schulman S · Thromb J · 2020 · Background
PubMed: PMID 27766049 · NCT05313620 · Colitis, Ulcerative
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
Patel-Hett S, Martin EJ, Mohammed BM, et al. · Haemophilia · 2020 · Background
PubMed: PMID 31336410 · NCT05313620 · Colitis, Ulcerative
A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.
Park SH, Kim YJ, Rhee KH, et al. · J Crohns Colitis · 2020 · Background
PubMed: PMID 30989166 · NCT05186623 · Colitis, Ulcerative
Hypercoagulability After Resection of Thoracic Malignancy: A Prospective Evaluation.
Mulder MB, Proctor KG, Valle EJ, et al. · World J Surg · 2020 · Background
PubMed: PMID 31407092 · NCT05313620 · Colitis, Ulcerative
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN, Raftis J, Wilson SJ, et al. · Arterioscler Thromb Vasc Biol · 2020 · Background
PubMed: PMID 32907366 · NCT05313620 · Colitis, Ulcerative
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB, Byers NL, Higgs RE, et al. · Arthritis Res Ther · 2020 · Background
PubMed: PMID 31375130 · NCT04332042
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
Harigai M · Rheumatology (Oxford) · 2020 · Background
PubMed: PMID 30806708 · NCT05246293 (RAILDTo) · Arthritis, Rheumatoid
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.
Esfahani K, Hudson M, Batist G, et al. · N Engl J Med · 2020 · Background
PubMed: PMID 32521140 · NCT04768504
The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A, Warner R, Johnson K, et al. · J Autoimmun · 2020 · Background
PubMed: PMID 31320177 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
The Effect of Immunosuppression on Coagulation After Liver Transplantation.
Bedreli S, Straub K, Achterfeld A, et al. · Liver Transpl · 2020 · Background
PubMed: PMID 31021493 · NCT05313620 · Colitis, Ulcerative

2019 (25 papers)

Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal.
Tsakok T, Jabbar-Lopez ZK, Smith CH, et al. · Br J Dermatol · 2019 · Trial result
PubMed: PMID 29399784 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Liu LY, King BA · J Investig Dermatol Symp Proc · 2019 · Trial result
PubMed: PMID 29273099 · NCT07101471 · Alopecia Areata
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL, Melmed GY, Vermeire S, et al. · Inflamm Bowel Dis · 2019 · Derived
PubMed: PMID 29850873 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
Tanaka Y, Sugiyama N, Toyoizumi S, et al. · Rheumatology (Oxford) · 2019 · Derived
PubMed: PMID 30137547 · NCT02281552 · Arthritis, Rheumatoid
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Klünder B, Mohamed MF, Othman AA, et al. · Clin Pharmacokinet · 2019 · Derived
PubMed: PMID 29076110 · NCT01741493 · Arthritis, Rheumatoid
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A, Sansaricq F, Cerise J, et al. · J Invest Dermatol · 2019 · Derived
PubMed: PMID 29452121 · NCT02299297 · Alopecia Areata
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P, Coates LC, FitzGerald O, et al. · Arthritis Res Ther · 2019 · Derived
PubMed: PMID 30373651 · NCT01882439 (OPAL BEYOND) · Arthritis, Psoriatic
Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC, Khanna T, Sallee B, et al. · Dermatol Ther · 2019 · Background
PubMed: PMID 30264512 · NCT06202560 (Tofacitinib) · Lichen Planus
Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension.
Vrigkou E, Tsangaris I, Bonovas S, et al. · Platelets · 2019 · Background
PubMed: PMID 30047809 · NCT05313620 · Colitis, Ulcerative
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ, McGonagle D, McInnes IB, et al. · Rheumatology (Oxford) · 2019 · Background
PubMed: PMID 29618084 · NCT06114407 · Spondylarthritis
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D, Baraliakos X, Gensler LS, et al. · Lancet · 2019 · Background
PubMed: PMID 30360970 · NCT05313620 · Colitis, Ulcerative
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.
Uzzan M, Tokuyama M, Rosenstein AK, et al. · Sci Transl Med · 2019 · Background
PubMed: PMID 30282696 · NCT05186623 · Colitis, Ulcerative
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B, Kopylov U, Yavzori M, et al. · Clin Gastroenterol Hepatol · 2019 · Background
PubMed: PMID 29223444 · NCT05186623 · Colitis, Ulcerative
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.
Stikvoort A, Chen Y, Rådestad E, et al. · Front Immunol · 2019 · Background
PubMed: PMID 28674539 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, et al. · N Engl J Med · 2019 · Background
PubMed: PMID 31553833 · NCT05313620 · Colitis, Ulcerative
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Sands BE, Sandborn WJ, Feagan BG, et al. · J Crohns Colitis · 2019 · Background
PubMed: PMID 29917064 · NCT05313620 · Colitis, Ulcerative
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV, et al. · N Engl J Med · 2019 · Background
PubMed: PMID 31553834 · NCT05186623 · Colitis, Ulcerative
Tracking JAKs in spondyloarthritis: rationale and expectations.
Miceli-Richard C, Dougados M · Ann Rheum Dis · 2019 · Background
PubMed: PMID 28314752 · NCT06114407 · Spondylarthritis
Treatment of Alopecia Areata With Tofacitinib.
Ibrahim O, Bayart CB, Hogan S, et al. · JAMA Dermatol · 2019 · Background
PubMed: PMID 28355451 · NCT03800979 · Alopecia Areata
Medical therapy for frontal fibrosing alopecia: A review and clinical approach.
Ho A, Shapiro J · J Am Acad Dermatol · 2019 · Background
PubMed: PMID 30953702 · NCT06202560 (Tofacitinib) · Lichen Planus
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
Danese S, Allez M, van Bodegraven AA, et al. · Dig Dis · 2019 · Background
PubMed: PMID 30726845 · NCT05313620 · Colitis, Ulcerative
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
Damsky W, Thakral D, Emeagwali N, et al. · N Engl J Med · 2019 · Background
PubMed: PMID 30586518 · NCT03910543 · Granuloma Annulare
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M, Garre A, Ricart E, et al. · Aliment Pharmacol Ther · 2019 · Background
PubMed: PMID 30281832 · NCT05313620 · Colitis, Ulcerative
A blood-based prognostic biomarker in IBD.
Biasci D, Lee JC, Noor NM, et al. · Gut · 2019 · Background
PubMed: PMID 31030191 · NCT05186623 · Colitis, Ulcerative
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A, Colombel JF, Ungaro R, et al. · Aliment Pharmacol Ther · 2019 · Background
PubMed: PMID 29430672 · NCT05186623 · Colitis, Ulcerative

2018 (31 papers)

Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis.
Tournadre A, Pereira B, Dutheil F, et al. · J Cachexia Sarcopenia Muscle · 2018 · Trial result
PubMed: PMID 28316139 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Alopecia areata.
Pratt CH, King LE, Messenger AG, et al. · Nat Rev Dis Primers · 2018 · Trial result
PubMed: PMID 28300084 · NCT06278402 · Alopecia Areata
Item Generation and Reduction Toward Developing a Patient-reported Outcome for Pediatric Ulcerative Colitis (TUMMY-UC).
Marcovitch L, Nissan A, Mack D, et al. · J Pediatr Gastroenterol Nutr · 2018 · Trial result
PubMed: PMID 27159210 · NCT04624230 · Colitis, Ulcerative
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M, Ko JM, Craiglow BG, et al. · JCI Insight · 2018 · Trial result
PubMed: PMID 27699252 · NCT02312882 · Alopecia Areata
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Panés J, Vermeire S, Lindsay JO, et al. · J Crohns Colitis · 2018 · Derived
PubMed: PMID 29028981 · NCT01465763 (OCTAVE) · Colitis, Ulcerative
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, et al. · Lancet · 2018 · Derived
PubMed: PMID 28629665 · NCT02187055 (ORAL STRATEGY)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S, Rosati E, Dowds CM, et al. · Gut · 2018 · Background
PubMed: PMID 29730603 · NCT05186623 · Colitis, Ulcerative
Ulcerative colitis.
Ungaro R, Mehandru S, Allen PB, et al. · Lancet · 2018 · Background
PubMed: PMID 27914657 · NCT05313620 · Colitis, Ulcerative
Frontal Fibrosing Alopecia: Update and Review of Challenges and Successes.
To D, Beecker J · J Cutan Med Surg · 2018 · Background
PubMed: PMID 29056083 · NCT06202560 (Tofacitinib) · Lichen Planus
Endoscopy in inflammatory bowel disease: advances in disease management.
Scoville EA, Schwartz DA · Gastrointest Endosc · 2018 · Background
PubMed: PMID 28886962 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC, Hider SL, Scott DL, et al. · Drug Saf · 2018 · Background
PubMed: PMID 29500799 · NCT05313620 · Colitis, Ulcerative
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.
Sakai R, Kondo T, Kurasawa T, et al. · Clin Rheumatol · 2018 · Background
PubMed: PMID 28733791 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases.
Rakowska A, Gradzińska A, Olszewska M, et al. · J Drugs Dermatol · 2018 · Background
PubMed: PMID 29036252 · NCT06202560 (Tofacitinib) · Lichen Planus
Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
Planell N, Masamunt MC, Leal RF, et al. · J Crohns Colitis · 2018 · Background
PubMed: PMID 28981629 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
Park SH, Aniwan S, Loftus EV, et al. · Curr Opin Pharmacol · 2018 · Background
PubMed: PMID 28992449 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Evaluation of hypercoagulability with rotational thromboelastometry in children with iron deficiency anemia.
Özdemir ZC, Düzenli Kar Y, Gündüz E, et al. · Hematology · 2018 · Background
PubMed: PMID 29544395 · NCT05313620 · Colitis, Ulcerative
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
Ng SC, Shi HY, Hamidi N, et al. · Lancet · 2018 · Background
PubMed: PMID 29050646 · NCT05313620 · Colitis, Ulcerative
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, et al. · Lancet Haematol · 2018 · Background
PubMed: PMID 28336242 · NCT05313620 · Colitis, Ulcerative
Can We Predict the Efficacy of Anti-TNF-α Agents?
Lopetuso LR, Gerardi V, Papa V, et al. · Int J Mol Sci · 2018 · Background
PubMed: PMID 28906475 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Effect of Albumin in Combination With Mannitol on Whole-blood Coagulation In Vitro Assessed by Thromboelastometry.
Lillemäe K, Laine AT, Schramko A, et al. · J Neurosurg Anesthesiol · 2018 · Background
PubMed: PMID 28498140 · NCT05313620 · Colitis, Ulcerative
Adaptation of Chinese and English versions of the Ankylosing Spondylitis quality of life (ASQoL) scale for use in Singapore.
Leung YY, Lee W, Lui NL, et al. · BMC Musculoskelet Disord · 2018 · Background
PubMed: PMID 28818056 · NCT06114407 · Spondylarthritis
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Jabbari A, Nguyen N, Cerise JE, et al. · Exp Dermatol · 2018 · Background
PubMed: PMID 27119625 · NCT06157905 · Alopecia Areata
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Hindryckx P, Vande Casteele N, Novak G, et al. · J Crohns Colitis · 2018 · Background
PubMed: PMID 28961959 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Noninfectious Manifestations and Complications of Chronic Granulomatous Disease.
Henrickson SE, Jongco AM, Thomsen KF, et al. · J Pediatric Infect Dis Soc · 2018 · Background
PubMed: PMID 29746679 · NCT05104723 · Colitis, Ulcerative
Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA, Ramadan HK, Ismael AA, et al. · Saudi J Gastroenterol · 2018 · Background
PubMed: PMID 28721978 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study.
Grant AL, Letson HL, Morris JL, et al. · J Orthop Surg Res · 2018 · Background
PubMed: PMID 29914535 · NCT05313620 · Colitis, Ulcerative
Ustekinumab to treat Crohn's disease.
Gisbert JP, Chaparro M · Gastroenterol Hepatol · 2018 · Background
PubMed: PMID 29042094 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
Feng T, Chen B, Li L, et al. · Inflamm Bowel Dis · 2018 · Background
PubMed: PMID 28644181 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Dulai PS, Boland BS, Singh S, et al. · Gastroenterology · 2018 · Background
PubMed: PMID 29857091 · NCT05186623 · Colitis, Ulcerative
Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E, Gisbert JP · Gastroenterol Hepatol · 2018 · Background
PubMed: PMID 26948838 · NCT03885713 (BioIBD) · Colitis, Ulcerative
JAK/STAT - Emerging Players in Metabolism.
Dodington DW, Desai HR, Woo M, et al. · Trends Endocrinol Metab · 2018 · Background
PubMed: PMID 29191719 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid

2017 (31 papers)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
van der Heijde D, Deodhar A, Wei JC, et al. · Ann Rheum Dis · 2017 · Trial result
PubMed: PMID 28130206 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Mohamed MF, Camp HS, Jiang P, et al. · Clin Pharmacokinet · 2017 · Trial result
PubMed: PMID 27272171 · NCT01741493 · Arthritis, Rheumatoid
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P, Hall S, FitzGerald O, et al. · N Engl J Med · 2017 · Trial result
PubMed: PMID 29045212 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis.
Marouen S, Barnetche T, Combe B, et al. · Clin Exp Rheumatol · 2017 · Trial result
PubMed: PMID 27974099 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY, Craiglow BG, Dai F, et al. · J Am Acad Dermatol · 2017 · Trial result
PubMed: PMID 27816293 · NCT07101471 · Alopecia Areata
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D, Rigby W, Azevedo VF, et al. · N Engl J Med · 2017 · Trial result
PubMed: PMID 29045207 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W, King BA · J Am Acad Dermatol · 2017 · Trial result
PubMed: PMID 28139263 · NCT06278402 · Alopecia Areata
Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases.
Benchimol EI, Bernstein CN, Bitton A, et al. · Am J Gastroenterol · 2017 · Trial result
PubMed: PMID 28417994 · NCT04624230 · Colitis, Ulcerative
Oral lichen planus: a literature review and update.
Alrashdan MS, Cirillo N, McCullough M, et al. · Arch Dermatol Res · 2017 · Trial result
PubMed: PMID 27349424 · NCT07131813 · Lichen Planus, Oral
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Winthrop KL, Wouters AG, Choy EH, et al. · Arthritis Rheumatol · 2017 · Derived
PubMed: PMID 28845577 · NCT02147587 · Arthritis, Rheumatoid
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Su C, Sands BE, et al. · N Engl J Med · 2017 · Derived
PubMed: PMID 28467869 · NCT01458951 (OCTAVE) · Colitis, Ulcerative
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA, Bissonnette R, Gooderham M, et al. · BMC Dermatol · 2017 · Derived
PubMed: PMID 27716172 · NCT01831466 · Psoriasis
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG, Østergaard M, Bowes MA, et al. · Ann Rheum Dis · 2017 · Derived
PubMed: PMID 27002108 · NCT01164579 · Arthritis, Rheumatoid
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB, Tanaka Y, Mariette X, et al. · Ann Rheum Dis · 2017 · Derived
PubMed: PMID 28143815 · NCT01164579 · Arthritis, Rheumatoid
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Bayart CB, DeNiro KL, Brichta L, et al. · J Am Acad Dermatol · 2017 · Derived
PubMed: PMID 28619556 · NCT02812342 · Alopecia Areata
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.
Yates M, Watts RA, Bajema IM, et al. · Ann Rheum Dis · 2017 · Background
PubMed: PMID 27338776 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.
Vuitton L, Marteau P, Sandborn WJ, et al. · Gut · 2017 · Background
PubMed: PMID 26353983 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
Viazis N, Giakoumis M, Bamias G, et al. · Dig Liver Dis · 2017 · Background
PubMed: PMID 27866814 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets.
van Unen V, Li N, Molendijk I, et al. · Immunity · 2017 · Background
PubMed: PMID 27178470 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan.
Tatsumi Y, Nakao YM, Masuda I, et al. · BMJ Open · 2017 · Background
PubMed: PMID 28093438 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Mass Cytometry: Single Cells, Many Features.
Spitzer MH, Nolan GP · Cell · 2017 · Background
PubMed: PMID 27153492 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Smolen JS, Aletaha D, Gruben D, et al. · Arthritis Rheumatol · 2017 · Background
PubMed: PMID 27907269 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L, et al. · Expert Rev Gastroenterol Hepatol · 2017 · Background
PubMed: PMID 27043489 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Panés J, Sandborn WJ, Schreiber S, et al. · Gut · 2017 · Background
PubMed: PMID 28209624 · NCT05104723 · Colitis, Ulcerative
Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized study.
Lee J, Jung CW, Jeon Y, et al. · PLoS One · 2017 · Background
PubMed: PMID 28715503 · NCT05313620 · Colitis, Ulcerative
The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Gisbert JP, Marín AC, Chaparro M, et al. · Am J Gastroenterol · 2017 · Background
PubMed: PMID 27002797 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG, Liu LY, King BA, et al. · J Am Acad Dermatol · 2017 · Background
PubMed: PMID 27816292 · NCT03800979 · Alopecia Areata
Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
Baraliakos X, Kiltz U, Peters S, et al. · Rheumatology (Oxford) · 2017 · Background
PubMed: PMID 27997346 · NCT06114407 · Spondylarthritis
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
Arbelaiz A, Azkargorta M, Krawczyk M, et al. · Hepatology · 2017 · Background
PubMed: PMID 28555885 · NCT03885713 (BioIBD) · Colitis, Ulcerative
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK, Speeckaert R, Desmet E, et al. · PLoS One · 2017 · Background
PubMed: PMID 27711196 · NCT06202560 (Tofacitinib) · Lichen Planus
Procoagulant profile in patients with immune thrombocytopenia.
Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, et al. · Br J Haematol · 2017 · Background
PubMed: PMID 27766635 · NCT05313620 · Colitis, Ulcerative

2016 (24 papers)

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, et al. · Br J Dermatol · 2016 · Trial result
PubMed: PMID 26357944 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. · J Rheumatol · 2016 · Trial result
PubMed: PMID 25593233 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.
Coates LC, Helliwell PS · J Rheumatol · 2016 · Trial result
PubMed: PMID 26669913 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J, Clark JD, Suárez-Fariñas M, et al. · J Allergy Clin Immunol · 2016 · Derived
PubMed: PMID 27059729 · NCT01710046
The epidemiology and risk factors of inflammatory bowel disease.
Ye Y, Pang Z, Chen W, et al. · Int J Clin Exp Med · 2016 · Background
PubMed: PMID 26885239 · NCT05313620 · Colitis, Ulcerative
Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.
Tsantes AE, Kyriakou E, Ikonomidis I, et al. · Medicine (Baltimore) · 2016 · Background
PubMed: PMID 27057830 · NCT05313620 · Colitis, Ulcerative
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
Tew GW, Hackney JA, Gibbons D, et al. · Gastroenterology · 2016 · Background
PubMed: PMID 26522261 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
Shah SC, Colombel JF, Sands BE, et al. · Aliment Pharmacol Ther · 2016 · Background
PubMed: PMID 26607562 · NCT03885713 (BioIBD) · Colitis, Ulcerative
"Family reunion"--A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines.
Rose-John S, Scheller J, Schaper F, et al. · Cytokine Growth Factor Rev · 2016 · Background
PubMed: PMID 26235233 · NCT04332042
Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
Niewiadomski O, Studd C, Hair C, et al. · J Crohns Colitis · 2016 · Background
PubMed: PMID 26129692 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
Nair N, Mei HE, Chen SY, et al. · Arthritis Res Ther · 2016 · Background
PubMed: PMID 25981462 · NCT03885713 (BioIBD) · Colitis, Ulcerative
The Role of Platelets in Venous Thromboembolism.
Montoro-García S, Schindewolf M, Stanford S, et al. · Semin Thromb Hemost · 2016 · Background
PubMed: PMID 26926584 · NCT05313620 · Colitis, Ulcerative
Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.
Lee S, Park HY, Kang SY, et al. · Oncotarget · 2016 · Background
PubMed: PMID 25980440 · NCT03598959 · Lymphoma, Extranodal NK-T-Cell
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
Kopylov U, Seidman E · Ther Adv Gastroenterol · 2016 · Background
PubMed: PMID 27366220 · NCT03885713 (BioIBD) · Colitis, Ulcerative
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
PubMed: PMID 25904741 · NCT07352566 · Psoriasis
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L, Smolen JS, Ramiro S, et al. · Ann Rheum Dis · 2016 · Background
PubMed: PMID 26644232 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.
Gordon JP, McEwan PC, Maguire A, et al. · Eur J Gastroenterol Hepatol · 2016 · Background
PubMed: PMID 25933126 · NCT05313620 · Colitis, Ulcerative
[Vedolizumab in the treatment of Crohn's disease].
Gisbert JP, Domènech E · Gastroenterol Hepatol · 2016 · Background
PubMed: PMID 25619903 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Clinical recovery from surgery correlates with single-cell immune signatures.
Gaudillière B, Fragiadakis GK, Bruggner RV, et al. · Sci Transl Med · 2016 · Background
PubMed: PMID 25253674 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.
Fleischmann RM, Huizinga TW, Kavanaugh AF, et al. · RMD Open · 2016 · Background
PubMed: PMID 27493790 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
Ding NS, Hart A, De Cruz P, et al. · Aliment Pharmacol Ther · 2016 · Background
PubMed: PMID 26515897 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
Dahlén R, Magnusson MK, Bajor A, et al. · Scand J Gastroenterol · 2016 · Background
PubMed: PMID 25877762 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG, King BA · JAMA Dermatol · 2016 · Background
PubMed: PMID 26107994 · NCT06202560 (Tofacitinib) · Lichen Planus
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.
Berti A, Cavalli G, Campochiaro C, et al. · Semin Arthritis Rheum · 2016 · Background
PubMed: PMID 25841802 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis

2015 (17 papers)

TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.
Toussirot É, Mourot L, Dehecq B, et al. · Eur J Nutr · 2015 · Trial result
PubMed: PMID 24173963 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
Craiglow BG, King BA · J Invest Dermatol · 2015 · Trial result
PubMed: PMID 24940651 · NCT06278402 · Alopecia Areata
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S, Radominski SC, Gomez-Reino JJ, et al. · Arthritis Rheumatol · 2015 · Derived
PubMed: PMID 25047021 · NCT01164579 · Arthritis, Rheumatoid
Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood.
Rosenbaum JT, Choi D, Wilson DJ, et al. · JAMA Ophthalmol · 2015 · Background
PubMed: PMID 25880323 · NCT03793439 · Sarcoidosis
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · Am J Gastroenterol · 2015 · Background
PubMed: PMID 26303131 · NCT05313620 · Colitis, Ulcerative
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C, Harness J, Tan H, et al. · J Eur Acad Dermatol Venereol · 2015 · Background
PubMed: PMID 23294276 · NCT06202560 (Tofacitinib) · Lichen Planus
Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort.
Machado P, Navarro-Compán V, Landewé R, et al. · Arthritis Rheumatol · 2015 · Background
PubMed: PMID 25332195 · NCT06114407 · Spondylarthritis
A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.
Khanna R, Bouguen G, Feagan BG, et al. · Inflamm Bowel Dis · 2015 · Background
PubMed: PMID 25029615 · NCT03885713 (BioIBD) · Colitis, Ulcerative
XELJANZ (Tofacitinib) for Chronic Plaque Psoriasis.
Gupta AK, Daigle D, Abramovits W, et al. · Skinmed · 2015 · Background
PubMed: PMID 26380510 · NCT06202560 (Tofacitinib) · Lichen Planus
Thrombosis in inflammatory bowel diseases: what's the link?
Giannotta M, Tapete G, Emmi G, et al. · Thromb J · 2015 · Background
PubMed: PMID 25866483 · NCT05313620 · Colitis, Ulcerative
Towards personalized care in IBD.
Gerich ME, McGovern DP · Nat Rev Gastroenterol Hepatol · 2015 · Background
PubMed: PMID 24345887 · NCT03885713 (BioIBD) · Colitis, Ulcerative
CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.
Fergusson JR, Smith KE, Fleming VM, et al. · Cell Rep · 2015 · Background
PubMed: PMID 25437561 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases.
Eftekhari P, Glaubitz L, Breidert M, et al. · Dig Dis · 2015 · Background
PubMed: PMID 24969293 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome.
Coelho MC, Vieira Neto L, Kasuki L, et al. · Clin Endocrinol (Oxf) · 2015 · Background
PubMed: PMID 24815846 · NCT05313620 · Colitis, Ulcerative
Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients.
Campello E, Spiezia L, Zabeo E, et al. · Thromb Res · 2015 · Background
PubMed: PMID 25592651 · NCT05313620 · Colitis, Ulcerative
Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up.
Banka N, Mubki T, Bunagan MJ, et al. · Int J Dermatol · 2015 · Background
PubMed: PMID 24738979 · NCT06202560 (Tofacitinib) · Lichen Planus
Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT, Fernández Bello I, Arias-Salgado EG, et al. · Thromb Haemost · 2015 · Background
PubMed: PMID 24500066 · NCT05313620 · Colitis, Ulcerative

2014 (12 papers)

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
Xing L, Dai Z, Jabbari A, et al. · Nat Med · 2014 · Background
PubMed: PMID 25129481 · NCT06202560 (Tofacitinib) · Lichen Planus
Frontal fibrosing alopecia: a multicenter review of 355 patients.
Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, et al. · J Am Acad Dermatol · 2014 · Background
PubMed: PMID 24508293 · NCT06202560 (Tofacitinib) · Lichen Planus
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
Stidham RW, Lee TC, Higgins PD, et al. · Aliment Pharmacol Ther · 2014 · Background
PubMed: PMID 24749763 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.
Smith JA, Colbert RA · Arthritis Rheumatol · 2014 · Background
PubMed: PMID 24504793 · NCT06114407 · Spondylarthritis
Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.
Seeley EH, Washington MK, Caprioli RM, et al. · Proteomics Clin Appl · 2014 · Background
PubMed: PMID 23382084 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Inflammatory bowel disease: an expanding global health problem.
M'Koma AE · Clin Med Insights Gastroenterol · 2014 · Background
PubMed: PMID 24833941 · NCT03885713 (BioIBD) · Colitis, Ulcerative
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Langford CA, Monach PA, Specks U, et al. · Ann Rheum Dis · 2014 · Background
PubMed: PMID 24323392 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity.
Fernández-Bello I, López-Longo FJ, Arias-Salgado EG, et al. · Orphanet J Rare Dis · 2014 · Background
PubMed: PMID 23711081 · NCT05313620 · Colitis, Ulcerative
Inhibiting Janus kinases to treat alopecia areata.
Divito SJ, Kupper TS · Nat Med · 2014 · Background
PubMed: PMID 25198048 · NCT03800979 · Alopecia Areata
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M, Salem M, Pedersen J, et al. · Pharmacol Res · 2014 · Background
PubMed: PMID 23827161 · NCT05313620 · Colitis, Ulcerative
East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.
Burisch J, Pedersen N, Čuković-Čavka S, et al. · Gut · 2014 · Background
PubMed: PMID 23604131 · NCT05313620 · Colitis, Ulcerative
Primary haemostasis: newer insights.
Berndt MC, Metharom P, Andrews RK, et al. · Haemophilia · 2014 · Background
PubMed: PMID 24762270 · NCT05313620 · Colitis, Ulcerative

2013 (12 papers)

Platelets in thrombosis and hemostasis: old topic with new mechanisms.
Wang Y, Andrews M, Yang Y, et al. · Cardiovasc Hematol Disord Drug Targets · 2013 · Background
PubMed: PMID 23030445 · NCT05313620 · Colitis, Ulcerative
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Papp KA, Menter A, Strober B, et al. · Br J Dermatol · 2013 · Background
PubMed: PMID 22924949 · NCT06202560 (Tofacitinib) · Lichen Planus
Ulcerative colitis.
Ordás I, Eckmann L, Talamini M, et al. · Lancet · 2013 · Background
PubMed: PMID 22914296 · NCT05313620 · Colitis, Ulcerative
Back to the future: oral targeted therapy for RA and other autoimmune diseases.
O'Shea JJ, Laurence A, McInnes IB, et al. · Nat Rev Rheumatol · 2013 · Background
PubMed: PMID 23419429 · NCT02535689 · Lupus Erythematosus, Systemic
JAKs and STATs in immunity, immunodeficiency, and cancer.
O'Shea JJ, Holland SM, Staudt LM, et al. · N Engl J Med · 2013 · Background
PubMed: PMID 23301733 · NCT02535689 · Lupus Erythematosus, Systemic
Frontal fibrosing alopecia: a review of 60 cases.
MacDonald A, Clark C, Holmes S, et al. · J Am Acad Dermatol · 2013 · Background
PubMed: PMID 22503342 · NCT06202560 (Tofacitinib) · Lichen Planus
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study.
Høivik ML, Moum B, Solberg IC, et al. · Gut · 2013 · Background
PubMed: PMID 22717453 · NCT05313620 · Colitis, Ulcerative
Lichen planopilaris is characterized by immune privilege collapse of the hair follicle's epithelial stem cell niche.
Harries MJ, Meyer K, Chaudhry I, et al. · J Pathol · 2013 · Background
PubMed: PMID 23788005 · NCT06202560 (Tofacitinib) · Lichen Planus
Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease.
Han NY, Choi W, Park JM, et al. · J Dig Dis · 2013 · Background
PubMed: PMID 23320753 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, et al. · N Engl J Med · 2013 · Background
PubMed: PMID 23964932 · NCT05186623 · Colitis, Ulcerative
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
D'Haens G, Feagan B, Colombel JF, et al. · Gastroenterology · 2013 · Background
PubMed: PMID 23000597 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Histopathology of scarring and nonscarring hair loss.
Childs JM, Sperling LC · Dermatol Clin · 2013 · Background
PubMed: PMID 23159175 · NCT06202560 (Tofacitinib) · Lichen Planus

2012 (14 papers)

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
Kingsley GH, Kowalczyk A, Taylor H, et al. · Rheumatology (Oxford) · 2012 · Trial result
PubMed: PMID 22344575 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
Baranauskaite A, Raffayová H, Kungurov NV, et al. · Ann Rheum Dis · 2012 · Trial result
PubMed: PMID 21994233 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.
Sherlock JP, Joyce-Shaikh B, Turner SP, et al. · Nat Med · 2012 · Background
PubMed: PMID 22772566 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Rosengren S, Corr M, Firestein GS, et al. · Ann Rheum Dis · 2012 · Background
PubMed: PMID 22121136 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R, Olsen T, Cui G, et al. · Scand J Gastroenterol · 2012 · Background
PubMed: PMID 22486187 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
Rieder F, Karrasch T, Ben-Horin S, et al. · J Crohns Colitis · 2012 · Background
PubMed: PMID 22405177 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface.
Presley LL, Ye J, Li X, et al. · Inflamm Bowel Dis · 2012 · Background
PubMed: PMID 21698720 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.
Peyrin-Biroulet L, Ferrante M, Magro F, et al. · J Crohns Colitis · 2012 · Background
PubMed: PMID 21939925 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Mucosal healing in inflammatory bowel diseases: a systematic review.
Neurath MF, Travis SP · Gut · 2012 · Background
PubMed: PMID 22842618 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.
Molodecky NA, Soon IS, Rabi DM, et al. · Gastroenterology · 2012 · Background
PubMed: PMID 22001864 · NCT05186623 · Colitis, Ulcerative
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Maeshima K, Yamaoka K, Kubo S, et al. · Arthritis Rheum · 2012 · Background
PubMed: PMID 22147632 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU, Dubrau C, Herlyn K, et al. · Ann Rheum Dis · 2012 · Background
PubMed: PMID 22021864 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
Extracellular matrix proteins in hemostasis and thrombosis.
Bergmeier W, Hynes RO · Cold Spring Harb Perspect Biol · 2012 · Background
PubMed: PMID 21937733 · NCT05313620 · Colitis, Ulcerative
A deep profiler's guide to cytometry.
Bendall SC, Nolan GP, Roederer M, et al. · Trends Immunol · 2012 · Background
PubMed: PMID 22476049 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2011 (13 papers)

Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.
Engvall IL, Tengstrand B, Brismar K, et al. · Arthritis Res Ther · 2011 · Trial result
PubMed: PMID 20964833 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
Helium in Anaesthesia.
Sykes WS, Lawrence RC · Br Med J · 2011 · Background
PubMed: PMID 20781696 · NCT03738956 · Axial Spondyloarthritis
Predicting response to Anti-TNF Agents for the treatment of crohn's disease.
Siegel CA, Melmed GY · Ther Adv Gastroenterol · 2011 · Background
PubMed: PMID 21180547 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
Nunes T, Barreiro-de Acosta M, Nos P, et al. · J Crohns Colitis · 2011 · Background
PubMed: PMID 21122572 · NCT05313620 · Colitis, Ulcerative
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
Machado P, Landewé R, Lie E, et al. · Ann Rheum Dis · 2011 · Background
PubMed: PMID 21068095 · NCT06114407 · Spondylarthritis
Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.
M'Koma AE, Seeley EH, Washington MK, et al. · Inflamm Bowel Dis · 2011 · Background
PubMed: PMID 20806340 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.
Lee JC, Lyons PA, McKinney EF, et al. · J Clin Invest · 2011 · Background
PubMed: PMID 21946256 · NCT05186623 · Colitis, Ulcerative
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K, Jesson MI, Li X, et al. · J Immunol · 2011 · Background
PubMed: PMID 21383241 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
Ford AC, Sandborn WJ, Khan KJ, et al. · Am J Gastroenterol · 2011 · Background
PubMed: PMID 21407183 · NCT05313620 · Colitis, Ulcerative
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR, Panaccione R, Higgins PD, et al. · Am J Gastroenterol · 2011 · Background
PubMed: PMID 21045814 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF, Rutgeerts P, Reinisch W, et al. · Gastroenterology · 2011 · Background
PubMed: PMID 21723220 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
Brophy DF, Martin EJ, Christian Barrett J, et al. · Haemophilia · 2011 · Background
PubMed: PMID 21362113 · NCT05313620 · Colitis, Ulcerative
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
Arijs I, Quintens R, Van Lommel L, et al. · Inflamm Bowel Dis · 2011 · Background
PubMed: PMID 20848504 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2010 (10 papers)

Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis.
Alkhalifah A, Alsantali A, Wang E, et al. · J Am Acad Dermatol · 2010 · Trial result
PubMed: PMID 20115945 · NCT03800979 · Alopecia Areata
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20647199 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
A brief course of anti-TNF-alpha therapy can cure recurrent episodes of HLA-B27-associated severe and refractory heel enthesitis.
Olivieri I, Giasi V, Scarano E, et al. · Clin Exp Rheumatol · 2010 · Background
PubMed: PMID 20149333 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z, Arijs I, De Hertogh G, et al. · Inflamm Bowel Dis · 2010 · Background
PubMed: PMID 20196149 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Risk assessment for recurrent venous thrombosis.
Kyrle PA, Rosendaal FR, Eichinger S, et al. · Lancet · 2010 · Background
PubMed: PMID 21131039 · NCT05313620 · Colitis, Ulcerative
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology, et al. · Am J Gastroenterol · 2010 · Background
PubMed: PMID 20068560 · NCT05313620 · Colitis, Ulcerative
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20393175 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Systematic review: the costs of ulcerative colitis in Western countries.
Cohen RD, Yu AP, Wu EQ, et al. · Aliment Pharmacol Ther · 2010 · Background
PubMed: PMID 20064142 · NCT05313620 · Colitis, Ulcerative
Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis.
Braun J, Inman R · Ann Rheum Dis · 2010 · Background
PubMed: PMID 20566619 · NCT03738956 · Axial Spondyloarthritis
Alopecia areata update: part II. Treatment.
Alkhalifah A, Alsantali A, Wang E, et al. · J Am Acad Dermatol · 2010 · Background
PubMed: PMID 20115946 · NCT03800979 · Alopecia Areata

2009 (8 papers)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.
Salliot C, van der Heijde D · Ann Rheum Dis · 2009 · Trial result
PubMed: PMID 19060002 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis.
Dalrymple JM, Stamp LK, O'Donnell JL, et al. · Arthritis Rheum · 2009 · Trial result
PubMed: PMID 18975321 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Early rheumatoid arthritis and body composition.
Book C, Karlsson MK, Akesson K, et al. · Rheumatology (Oxford) · 2009 · Trial result
PubMed: PMID 19602478 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.
Sieper J, Rudwaleit M, Baraliakos X, et al. · Ann Rheum Dis · 2009 · Background
PubMed: PMID 19433414 · NCT06114407 · Spondylarthritis
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.
Rudwaleit M, van der Heijde D, Landewé R, et al. · Ann Rheum Dis · 2009 · Background
PubMed: PMID 19297344 · NCT06114407 · Spondylarthritis
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
Olsen T, Goll R, Cui G, et al. · Cytokine · 2009 · Background
PubMed: PMID 19286392 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry.
Nanni P, Mezzanotte L, Roda G, et al. · J Proteomics · 2009 · Background
PubMed: PMID 19168159 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
Arijs I, Li K, Toedter G, et al. · Gut · 2009 · Background
PubMed: PMID 19700435 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2008 (7 papers)

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B, Teller C, Yamauchi P, et al. · Br J Dermatol · 2008 · Trial result
PubMed: PMID 18503600 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Current directions in IBD therapy: what goals are feasible with biological modifiers?
Sandborn WJ · Gastroenterology · 2008 · Background
PubMed: PMID 18848556 · NCT05186623 · Colitis, Ulcerative
Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
Nanni P, Parisi D, Roda G, et al. · Rapid Commun Mass Spectrom · 2008 · Background
PubMed: PMID 18022963 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
Meuwis MA, Fillet M, Lutteri L, et al. · Clin Biochem · 2008 · Background
PubMed: PMID 18489908 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Triggers, targets and treatments for thrombosis.
Mackman N · Nature · 2008 · Background
PubMed: PMID 18288180 · NCT05313620 · Colitis, Ulcerative
Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Lak M, Scharling B, Blemings A, et al. · Haemophilia · 2008 · Background
PubMed: PMID 18070065 · NCT05313620 · Colitis, Ulcerative
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.
Jandus C, Bioley G, Rivals JP, et al. · Arthritis Rheum · 2008 · Background
PubMed: PMID 18668556 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic

2007 (8 papers)

Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.
Turner D, Otley AR, Mack D, et al. · Gastroenterology · 2007 · Trial result
PubMed: PMID 17681163 · NCT04624230 · Colitis, Ulcerative
Unravelling the pathogenesis of inflammatory bowel disease.
Xavier RJ, Podolsky DK · Nature · 2007 · Background
PubMed: PMID 17653185 · NCT05186623 · Colitis, Ulcerative
Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A, Iorizzo M, Botta GL, et al. · J Eur Acad Dermatol Venereol · 2007 · Background
PubMed: PMID 17062039 · NCT03800979 · Alopecia Areata
Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
Shkoda A, Werner T, Daniel H, et al. · J Proteome Res · 2007 · Background
PubMed: PMID 17330946 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA, Sandborn WJ, Gassull M, et al. · Gastroenterology · 2007 · Background
PubMed: PMID 17241860 · NCT03885713 (BioIBD) · Colitis, Ulcerative
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
Hellmich B, Flossmann O, Gross WL, et al. · Ann Rheum Dis · 2007 · Background
PubMed: PMID 17170053 · NCT04871191 (SATELITE) · Granulomatosis with Polyangiitis
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
D'Haens G, Sandborn WJ, Feagan BG, et al. · Gastroenterology · 2007 · Background
PubMed: PMID 17258735 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Trends in hospitalization rates for inflammatory bowel disease in the United States.
Bewtra M, Su C, Lewis JD, et al. · Clin Gastroenterol Hepatol · 2007 · Background
PubMed: PMID 17382602 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2006 (4 papers)

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G, Sandborn WJ, Feagan BG, et al. · Gut · 2006 · Background
PubMed: PMID 16603634 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
Taylor W, Gladman D, Helliwell P, et al. · Arthritis Rheum · 2006 · Background
PubMed: PMID 16871531 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
The histopathology of primary cicatricial alopecia.
Sperling LC, Cowper SE · Semin Cutan Med Surg · 2006 · Background
PubMed: PMID 16616302 · NCT06202560 (Tofacitinib) · Lichen Planus
Comparative proteomic studies on the pathogenesis of human ulcerative colitis.
Hsieh SY, Shih TC, Yeh CY, et al. · Proteomics · 2006 · Background
PubMed: PMID 16947118 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2005 (5 papers)

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
Fraser AD, van Kuijk AW, Westhovens R, et al. · Ann Rheum Dis · 2005 · Trial result
PubMed: PMID 15528283 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, et al. · N Engl J Med · 2005 · Background
PubMed: PMID 16339095 · NCT05186623 · Colitis, Ulcerative
Psoriasis: epidemiology, clinical features, and quality of life.
Langley RG, Krueger GG, Griffiths CE, et al. · Ann Rheum Dis · 2005 · Background
PubMed: PMID 15708928 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
Gladman DD, Antoni C, Mease P, et al. · Ann Rheum Dis · 2005 · Background
PubMed: PMID 15708927 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
Daperno M, D'Haens G, Van Assche G, et al. · Gastrointest Endosc · 2005 · Background
PubMed: PMID 15472670 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2004 (4 papers)

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.
Loftus EV · Gastroenterology · 2004 · Background
PubMed: PMID 15168363 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction.
Kane D, Jensen LE, Grehan S, et al. · J Rheumatol · 2004 · Background
PubMed: PMID 15229943 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic
Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli.
Hardwidge PR, Rodriguez-Escudero I, Goode D, et al. · J Biol Chem · 2004 · Background
PubMed: PMID 14988394 · NCT03885713 (BioIBD) · Colitis, Ulcerative
Inflammatory bowel disease: the role of environmental factors.
Danese S, Sans M, Fiocchi C, et al. · Autoimmun Rev · 2004 · Background
PubMed: PMID 15288007 · NCT05313620 · Colitis, Ulcerative

2003 (3 papers)

The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease.
Otley A, Smith C, Nicholas D, et al. · J Pediatr Gastroenterol Nutr · 2003 · Trial result
PubMed: PMID 12394384 · NCT04624230 · Colitis, Ulcerative
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
Braun J, Pham T, Sieper J, et al. · Ann Rheum Dis · 2003 · Background
PubMed: PMID 12922952 · NCT03738956 · Axial Spondyloarthritis
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.
Boonen A, van der Heijde D, Landewé R, et al. · Ann Rheum Dis · 2003 · Background
PubMed: PMID 12860728 · NCT03738956 · Axial Spondyloarthritis

2002 (2 papers)

Platelets and thrombin generation.
Monroe DM, Hoffman M, Roberts HR, et al. · Arterioscler Thromb Vasc Biol · 2002 · Background
PubMed: PMID 12231555 · NCT05313620 · Colitis, Ulcerative
Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
Barceló-Batllori S, André M, Servis C, et al. · Proteomics · 2002 · Background
PubMed: PMID 11987129 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2001 (2 papers)

Performance of a new pubertal self-assessment questionnaire: a preliminary study.
Taylor SJ, Whincup PH, Hindmarsh PC, et al. · Paediatr Perinat Epidemiol · 2001 · Trial result
PubMed: PMID 11237120 · NCT04624230 · Colitis, Ulcerative
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
Anderson JJ, Baron G, van der Heijde D, et al. · Arthritis Rheum · 2001 · Background
PubMed: PMID 11508441 · NCT03738956 · Axial Spondyloarthritis

2000 (2 papers)

Lichen planus.
Katta R · Am Fam Physician · 2000 · Trial result
PubMed: PMID 10865927 · NCT07131813 · Lichen Planus, Oral
Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register.
Haugeberg G, Uhlig T, Falch JA, et al. · Arthritis Rheum · 2000 · Trial result
PubMed: PMID 10728744 · NCT04175886 (TOFAT) · Arthritis, Rheumatoid

1998 (1 paper)

Patterns of cytokine production in psoriatic synovium.
Ritchlin C, Haas-Smith SA, Hicks D, et al. · J Rheumatol · 1998 · Background
PubMed: PMID 9712099 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic

1997 (1 paper)

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
Partsch G, Steiner G, Leeb BF, et al. · J Rheumatol · 1997 · Background
PubMed: PMID 9058659 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic

1996 (1 paper)

PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology.
Taylor CR, Hawk JL · Br J Dermatol · 1996 · Background
PubMed: PMID 8547044 · NCT03800979 · Alopecia Areata

1994 (1 paper)

Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution.
Kossard S · Arch Dermatol · 1994 · Background
PubMed: PMID 8002649 · NCT06202560 (Tofacitinib) · Lichen Planus

1991 (1 paper)

In vitro testing method of polymers candidate destined for contact with blood.
Szymonowicz M, Lowkis B · Polim Med · 1991 · Background
PubMed: PMID 2151779 · NCT06202560 (Tofacitinib) · Lichen Planus

1987 (1 paper)

Psoriatic arthritis (PSA)--an analysis of 220 patients.
Gladman DD, Shuckett R, Russell ML, et al. · Q J Med · 1987 · Trial result
PubMed: PMID 3659255 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic

1976 (5 papers)

Light-induced changes of absorbance and electron spin resonance in small photosystem II particles.
Van Gorkom HJ, Pulles MP, Wessels JS, et al. · Biochim Biophys Acta · 1976 · Background
PubMed: PMID 62 · NCT06202560 (Tofacitinib) · Lichen Planus
Coronary vascular and myocardial responses to carotid body stimulation in the dog.
Ehrhart IC, Parker PE, Weidner WJ, et al. · Am J Physiol · 1976 · Background
PubMed: PMID 2017 · NCT06202560 (Tofacitinib) · Lichen Planus
Biochemical and electrophoretic studies of erythrocyte pyridoxine kinase in white and black Americans.
Chern CJ, Beutler E · Am J Hum Genet · 1976 · Background
PubMed: PMID 2009 · NCT06202560 (Tofacitinib) · Lichen Planus
Prophylactic antiarrhythmic drug therapy in acute myocardial infarction.
Binnion PF, Das Gupta R · Cardiovasc Clin · 1976 · Background
PubMed: PMID 145 · NCT06202560 (Tofacitinib) · Lichen Planus
The effects of the continuous administration of N,N-dimethyl-4-phenylazoaniline (DAB) on the activities and the inducibilities of some drug-metabolizing enzymes in rat liver.
Autrup H, Thurlow BJ, Warwick GP, et al. · Chem Biol Interact · 1976 · Background
PubMed: PMID 148 · NCT06202560 (Tofacitinib) · Lichen Planus

1973 (1 paper)

Familial occurrence of psoriatic arthritis.
Moll JM, Wright V · Ann Rheum Dis · 1973 · Background
PubMed: PMID 4715537 · NCT03736161 (PsOLSET-BD) · Arthritis, Psoriatic

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 08 May 2026 19:19:51 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).